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ABSTRACT 
Upasana Niyogi. M.S. Department of Microbiology and Immunology, Wright State 
University, 2016. Adeno-associated virus–VEGF-165 mediated modification of adipose 
derived stem cells for cell therapy 
 
Chronic wounds have become a major clinical and economic burden in our 
society. New approaches that accelerate wound healing are desperately needed. 
Angiogenesis and vascularization play a critical role in healing. One of the essential 
angiogenic factors that promote the formation of vascular beds is vascular endothelial 
growth factor (VEGF).  Moreover, adipose-derived stem cells (ASC), through their 
regeneration and differentiation properties, may promote healing when transplanted into a 
wound bed. I have proposed to develop a novel organotypic wound model to facilitate the 
study of wound healing process. I hypothesize that administration of genetically-modified 
ASC secreting VEGF via an adeno-associated viral vector serotype (AAV5) directly into 
the wound site will accelerate rejuvenation of ischemic tissue. To test this hypothesis, the 
VEGF-165 gene was synthesized (IDT) and cloned (Clontech) into two AAV5 plasmids, 
pAAV5-CMV-GFP and pAAV5-CAG-GFP and transfected in HEK293, Cos-7 and 
primary ASC cells for gene expression. Based on the higher transfection efficiency and 
VEGF secretion in pAAV5-CAG-VEGF-GFP, AAV5-CAG-VEGF-GFP virus was 
produced by the University of Iowa using the Baculovirus system. I used AAV5-CAG-
VEGF-GFP and AAV5-CMV-GFP (control virus) to transduce the ASC. Wound healing 
assays in vitro measured by scratch assay were performed on monolayers of ASC and 
were observed for healing.  In vivo wound healing assay was performed on 2mm or 3mm 
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organotypic wound models by treating them with ASC-AAV5-CAG-VEGF-GFP, ASC-
AAV5-CMV-GFP, non-transduced ASC or ASC media. In vitro wound healing assays 
showed complete closure of non-transduced ASC in three days whereas the ASC-AAV5-
CAG-VEGF-GFP healed within two days indicating the efficiency of VEGF in 
accelerating closure. In vivo wound healing assays on organotypic wounds showed some 
closure in wounds treated with ASC compared to control wounds treated with media 
alone.  However wounds treated with ASC-AAV5-CAG-VEGF-GFP facilitated enhanced 
in complete closure compared to non-transduced ASC-treated wounds. No significant 
difference was observed between ASC-AAV5-CMV-GFP or non-transduced ASC treated 
wounds. We observed similar results in both 2 mm or 3 mm wounded models and with 
autologous or allogenic stem cells. Moreover, red light therapy (670 nm) also caused 
partial closure of wounds. Future studies should involve personalization of the wound 
model system depending on patient’s disease condition and developing ASC therapy with 
a cocktail of growth factors that can facilitate complete wound closure.  
iv 
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Chapter 1: Introduction 
1.1. Human Skin 
The human skin is the largest organ in the body with a surface area of 1.8 m2 and 
accounting for almost 15% of the total human body weight (Kanitakis et al., 2002). The 
primary function of skin is for thermoregulatory maintenance of the body temperature 
and also as a physical barrier protecting the body from chemicals, ultraviolet radiation, 
toxins, microorganisms, trauma and injury (Elias et al., 2005). Skin also plays a role in 
sensing touch, pain, temperature and in immune regulation.  
Skin consists of two layers epidermis and dermis separated by the basement 
membrane (shown in figure 1). The epidermis is the outer layer of the skin which is 
constantly shedding and regenerating and acts as a protective barrier. The inner layer of 
the skin, the dermis, is embedded in the third layer and acts as an insulator, providing 
structural support to the skin (Breitkreutz et al., 2013).  
1.1.1. Epidermis 
Epidermis is the outer layer of the skin made up of multilayered epithelium. The 
five distinct sublayers of the epidermis are called the stratum corneum, stratum lucidum, 
stratum granulosum, stratum spinosum, and stratum basale.  The predominant cells of the 
epidermis are keratinocytes that synthesize keratin. Under normal circumstances the only 
mitotically active layer of the epidermis is the basal layer (Blanpain et al., 2006).  
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Figure 1: Anatomy of skin 
Schematic representation of the layers of human skin along with sublayers and 
appendages.  
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The superficial epidermis consists of dead cells that are constantly shed and replaced by 
new sets of keratinocytes that migrate from the basal layer to the surface of the skin by a 
process known as keratinization. 
In thick skin, the stratum corneum is the topmost layer of the skin and mainly 
consists of about 20-30 layers of horny cells or corneocytes, and is rich in proteins and 
low in lipids. The thick layer acts as a protective layer and also prevents loss of water 
from the skin. The next layer, stratum lucidum is mainly present in the soles of the hands 
and feet, also preventing water loss from the skin. Stratum granulosum is the granular 
layer made up of one to three layers of stratified squamous cells and consists of lamellar 
granules and tonofibrils. It is present in the soles of feet and the palms of hands. The 
fourth layer stratum spinosum, also known as the spinous layer lies just above the basal 
layer and are connected by desmosomes which appear as prickles under a microscope. 
(Chu, 2008). The basal layer also known as the stratum germinativim, is single layered 
and mainly consists of the dividing and non-dividing keratinocytes that attach to the 
basement membrane. It is also attached to the suprabasal squamous cells by desmosomes. 
The basal layer also consists of melanocytes, which protect the body from UV radiation 
and chronic light. Lastly, the basal layer contains Merkel cells, which play a role in 
perception of touch. 
1.1.2. Basement membrane 
The epidermis and dermis are separated from each other by the basal lamina or 
the basement membrane, which acts as a gate keeper and controls cell trafficking. It is 
through this layer that the nutrients diffuse into the epidermis. The basement membrane 
binds to many cytokines and releases them under conditions of physiological remodeling. 
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The structure of the basement membrane is very irregular and flattens with age. It links 
the basal keratinocytes to the dermis. The basal lamina is made up of type IV collagen, 
anchoring fibrils and dermal microfilaments. It provides support to the epidermis, 
establishes cell polarity, and organizes the arrangement of cytoskeleton in basal cells 
(Breitkreutz et al., 2013). 
1.1.3. Dermis 
The inner layer of skin is the dermis which consists mostly of fibroblasts, mast 
cells and histiocytes. The dermis provides elasticity and tensile strength to skin, 
protecting it from mechanical injury (Burr et al., 2005). The dermis consists of two 
layers: the papillary layer and the reticular layer. The papillary layer contains nerves and 
capillaries which provide nutrients to the epidermis while the reticular layer consists of 
collagen and elastin that allow the dermis to stretch and contract. With age the amount of 
collagen and elastin decrease, while elastin also loses its elastic nature. This loss of 
elasticity appears as wrinkles on skin. (Tortora et al., 2009). The dermis also consists of 
eccrine glands, apocrine glands, sebaceous glands, ceruminous glands, blood vessels, and 
hair follicles especially in the forehead, palm, in groin, and axillae. 
1.2. Wounds 
 A wound is defined as an injury in the skin thereby causing disruption or damage 
to skin. It can be a simple break in the epidermis layer or a deeper injury or cut in the 
dermal and the subcutaneous fat layer (Velnar et al., 2009). It can be caused due to burns, 
traumatic lacerations, infections, radiation, pressure ulcers, diabetic ulcers, ischemia  or 
other dermatologic conditions A completely healed wound is the one where the skin has 
regained its normal anatomy and function (Velnar et al., 2009).  
4 
 
1.2.1. Classification of wounds  
 Wounds, depending on the type, can take variable time to heal (Falanga, 2005). 
Wounds can be categorized as acute or chronic wounds depending on the time they take 
to heal. Acute wounds are defined as the wounds which heal in an orderly and timely 
manner within a month and restore the normal integrity and anatomical functions of the 
skin membrane (Velnar et al., 2009). By contrast, chronic wounds are defined as those 
that fail to heal or regain the structural and functional integrity of the skin in an orderly 
process within a period of three months (Mustoe et al., 2006). 
1.2.2. Chronic wounds  
Chronic wounds are a major burden on our society. Nearly, 6.5 million Americans 
suffer from wounds that do not heal, costing healthcare almost $25 billion a year (Sen et 
al., 2009). Though the onset of chronic wounds is via acute wounds, factors like impaired 
neovascularization, prolonged inflammation, persistent infection, desiccation, reduced 
growth factors, drug resistance, diabetes, immune status, and nutritional status can 
compromise healing (Falanga et al., 2005).  
1.2.3. Wound healing process 
The normal wound healing process consists of four phases: hemostasis, 
inflammatory phase, proliferative phase and matrix remodeling, and scar formation. 
(Broughton et al., 2009). Wound healing is a complex process requiring a regulated 
combination of cell proliferation and migration, vascularization, angiogenesis, re-
epithelization, extracellular matrix deposition, and remodeling (Guo et al., 2010). The 
first phase hemostasis starts immediately after injury, when the blood vessels constrict to 
protect the vascular system. Fibrins prevent blood loss and protect the damaged area from 
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bacterial entry (Velnar et al., 2009). Proinflammatory cytokines and growth factors like 
FGF (fibroblast growth factor), TGF (transforming growth factor), EGF (epithelial 
growth factor), and PDGF (platelet derived growth factor) are released into the wound 
site. Once the bleeding is controlled, inflammatory cells such as macrophages and 
neutrophils are attracted to the wound site. Previously constricted blood vessels now open 
up by vasodilation and allow macrophages to enter. Neutrophils clear out the invading 
microbes and the macrophages clear the apoptotic cells including the neutrophils (Guo et 
al., 2010). The inflammatory and proliferative phases overlap with one another. The 
proliferative phase is characterized by the entry of fibroblasts into the wounds and 
deposition of collagen, glycosaminoglycans, and proteoglycans, which are important 
components of extracellular matrix (ECM) (Guo et al., 2010). In the last phase, the 
wound enters the remodeling phase, where collagen is re-arranged, new blood vessels are 
formed to strengthen vascular capillaries, scarring continues and the tensile strength of 
the new skin gradually improves (Falanga et al., 2005).  
1.2.4. Factors affecting wound healing 
 Various factors contribute to impaired wound healing. These include local factors 
which directly affect the healing process and systemic factors like the overall health or 
the nutritional status of the individual (Guo et al., 2010).  Examples of local factors are 
infection and oxygenation. Oxygenation plays an important role in wound healing. 
Hypoxic conditions in healthy patients can initiate the wound healing process by 
angiogenesis and secretion of growth factors. However, unhealthy patients with chronic 
wounds or microvascular insufficiency are not able to respond physiologically to hypoxia 
to promote healing. Wound infection typically occur a week or so after injury. The 
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majority of the infections are bacterial. Rarely fungal or viral infection can be seen in 
immunocompromised patients. 
Systemic factors include age, sex hormones, stress, nutrition, disease, alcoholism, 
and smoking (Guo et al., 2010). Elderly people are more prone to suffering from chronic 
wounds because of delays in epithelialization, collagen synthesis, and angiogenesis. Aged 
males are more susceptible to impaired chronic wound healing because androgens 
negatively regulate wound healing, whereas estrogen in aged females positively regulate 
wound healing by upregulating regeneration, matrix production, epidermal function, 
(Gilliver et al., 2007). Stress can substantially delay wound healing by upregulating the 
level of glucocorticoids and by decreasing secretion of proinflammatory cytokines, 
macrophages, and neutrophils in the wound site. Alcohol consumption and smoking 
exposes patients to heart and vascular disease, stroke, lung disease, and also to higher risk 
of infection by decreasing host resistance (Guo et al., 2010). Carbohydrates, fats, 
proteins, vitamins, minerals are all necessary to facilitate proper healing, and deficiency 
in any of these can contribute to impaired wound healing (Falanga et al., 2005).  
1.2.5. Treatments for chronic wounds 
Current approaches towards the treatment of chronic wounds include skin 
grafting, hyperbaric oxygenation, and amputation. However, therapeutic limitations of 
these traditional approaches include tendon adhesions, nerve entrapment, and 
neuropathies inflicting further functional deficits and atrophy to a wounded extremity 
(Diegelmann et al., 2004). Hence, new strategies for therapy have to be developed.  
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1.3. Skin substitutes 
 Skin substitutes are heterogenous materials used to cover skin defects thereby 
aiding in temporary or permanent wound healing (Singh et al., 2012). Skin substitutes 
can be classified into biological and synthetic substitutes. These should be easily 
available, easy to store and use, should be able to prevent infection, survive in hypoxic 
conditions and also be cost effective (Nathoo et al., 2014). 
1.3.1. Biological skin substitutes 
 Biological skin substitutes have an intact extracellular matrix thus promoting 
enhanced epithelialization and dermis formation. However, they take a longer time to 
become vascularized because of its slow integration process (Halim et al., 2010). Some 
of the widely used biological skin substitutes include xenografts, allografts, and 
autografts. 
 Autografts are tissues grafted from the patient’s body. They can be partial 
thickness (with the epidermis and a part of the dermis layer) or full thickness (with the 
entire epidermis and dermis layer). 
Biosynthetic skin products 
 Xenografts are tissues obtained from other species and are often used as a wound 
covering material. They can temporarily cover partial thickness burns, but there are 
eventually rejected by the host (Halim et al., 2010). Allografts are tissues obtained from 
another individual of the same species. They can be vascularized, promote angiogenesis, 
secrete cytokines and growth factors, and prevent bacterial colony formation and 
desiccation of wound beds (Singh et al., 2012). 
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1.3.2. Synthetic skin substitutes 
 Synthetic skin substitutes can be either cellular or acellular, and are obtained from 
natural or synthetic sources. Natural sources include cadaveric skin free of cellular 
components, but containing proteins and collagen (Singh et al., 2012) Synthetic sources 
can be in the form of a degradable polymer, with types including Biobrane®, Integra®, 
Alloderm®, Apligraft®, Matriderm®. 
 Biobrane® is a bi-laminated membrane made of nylon mesh (acting as the dermal 
layer) and a silicone membrane (as the epidermal layer) embedded into the collagen 
matrix (Halim et al., 2010).  It is used as a temporary skin substitute and is readily 
available and easy to use, but it brings along some risks of infection (Alrubaiy et al., 
2009). Integra® is a bi-layered skin substitute made of silicone as the epidermal layer, and 
bovine collagen and shark chondroitin-6-sulphate glycosaminoglycan as the dermal layer. 
It leads to revascularization of wounds within three weeks of implantation, but can also 
cause accumulation of fluid near wound site thus leading to a chance of infection (Nathoo 
et al., 2014). Alloderm® is made from cadaveric skin wherein the epidermis and the 
cellular components are removed, but it provides a good matrix for growth of fibroblast 
and endothelial cells (Alrubaiy et al., 2009). Apligraft® is bi-layered and is made up of 
type I bovine collagen and allogenic keratinocyte and neonatal fibroblast. When used 
with autografts it shows the best results. It can be used for burns, partial thickness 
wounds, or full thickness wounds. A limitation of Apligraft® is that it has a shelf life of 
only 5 days, hence it has to be prepared fresh before use. (Singh et al., 2012).  
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1.4. Stem cells in wound healing 
Stem cells play a pivotal role in wound healing by promoting tissue regeneration. 
Epidermal stem cells, which are present in the epidermis and the bulge of hair follicles, 
promote keratinocyte migration and promote epithelialization. (Gue et al., 2010). 
Mesenchymal stem cells differentiate into different lineages such as osteoblasts, 
chondrocytes, adipocytes, keratinocytes, and fibroblasts, as well as promoting wound 
healing (Falanga et al., 2005). Hematopoietic stem cells differentiate into blood cells and 
near the wound site they regulate proliferation and migration of epithelial and dermal 
MSC thus inducing wound healing (Wu et al., 2007). 
1.5. Adipose derived stem cells 
Adipose derived stem cells (ASCs), through their regenerative properties, induce 
healing of a wound when transplanted onto the wound bed of mice models. ASCs are 
multipotent in nature, secrete growth factors, promote angiogenesis, and differentiate into 
multiple lineages upon induction (Kim et al., 2007). The benefits of ASCs over bone 
marrow stem cells include achievement of higher yields upon isolation from the donor 
(nearly 40 fold) and a procedure that is overall less invasive to the patient, resulting in 
less donor morbidity (Zuk et al., 2002, Kern et al., 2006). Their ease of isolation, 
longtime preservation, and capacity to survive in hypoxic conditions makes them ideal 
cell therapeutic candidates (Gonda et al., 2008).  Moreover, since they are isolated from 
the patient’s own body, the chance of immune rejection extremely low. 
1.5.1. Localization and characterization of adipose derived stem cells 
  ASCs are typically obtained from liposuction or lipectomy, are digested 
with collagenase, and subjected to centrifugation (Figure 2). The stromal vascular 
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fraction thus obtained, are seeded and expanded in culture (Hassan et al., 2014). The 
growth and differentiation capacity of the ASCs depends on the site from where they are 
extracted. ASCs obtained from superficial abdominal layer are more susceptible to 
differentiation than ASCs obtained from subcutaneous fats. Additionally, ASCs 
differentiating potential is higher in younger people than the elderly (Scripper et al., 
2008). ASCs characterization is analyzed by the expression of positive surface markers 
like CD13, CD34, CD36, CD44, CD73, CD90, CD105, Stro-1 and by negative markers 
like CD31, CD45, and CD106. (Musina et al., 2005).  By their autocrine activity ASCs 
promote re-epithelialization and fibroblast proliferation (Kim et al., 2007).  
1.5.2. ASC as a regenerative medicine for wound healing 
  ASCs induce wound healing by stimulating collagen production, 
keratinocyte and fibroblast proliferation, angiogenesis, epithelialization to potentiate 
wound healing (Kim et al., 2007). ASCs administration in diabetic mice accelerates 
wound healing by neovascularization and angiogenesis. (Ebrahimian et al., 2009). ASCs 
when co-cultured with fibroblasts increase the migration capacity of the fibroblasts and 
thus potentiate wound healing (Kim et al., 2007). Hypoxic conditions upregulate ASCs 
activity by enhancing angiogenesis, secretion of growth factors and anti-apoptotic factors 
(Hassan et al., 2014). ASCs promote tissue regeneration and neovessel formation in 
severely radiation-damaged tissues (Rigotti et al., 2007).  ASCs also secrete growth 
factors like EGF, FGF, PDGF, KGF, and VEGF, which potentiate healing in acute and 
chronic wounds (Galliano et al., 2004). 
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Figure 2: Schematic representation of extraction of ASCs from a 
patient’s body and expansion in cell culture for transplantation 
into patients. 
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1.6. Vascular endothelial growth factor (VEGF) 
Angiogenesis and vascularization play a critical role in healing, especially in the 
proliferative phase of wound healing, resulting in the formation of new blood vessels that 
deliver oxygen, nutrients, and essential growth factors to injured tissues (Jacobi et al., 
2004). Vascular endothelial growth factor (VEGF), also known as vascular permeability 
factor (VPF) is one of the essential angiogenic factors promoting the development of the 
capillary network in ischemic tissues (Jacobi et al., 2004). VEGF is considered to be one 
of the most potent factors in the formation of blood vessels. It is a 34-42 kDa homodimer 
protein. It plays a role in proliferation and differentiation of endothelial cells, degradation 
of basement membranes, and lumen formation (Leung et al., 1989 as reviewed by Bryne 
et al., 2005). VEGF is also a chemotactic agent for macrophages and monocytes, thereby 
attracting them to the site of inflammation (Clauss et al., 1990 as reviewed by Bryne et 
al., 2005). VEGF is produced by macrophages, platelets, neutrophils, endothelial cells, 
fibroblasts and smooth muscle cells (Nissen et al., 1998 as reviewed by Bao et al., 2009). 
1.6.1. VEGF isoforms 
The amino acid structure of VEGF shares approximately 20% of its homology 
with the PDGF superfamily (Neufeld et al., 1999 as reviewed by Bryne et al., 2005). The 
VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF–D, VEGF-E and PLGF. 
Exons 1-5 are conserved in all VEGF-A forms (Figure 3). Alternative splicing in the 
exon 6 and 7 of the VEGF mRNA shows that there are 5 isoforms of VEGF, namely 
VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206 consisting of 121, 145, 165, 189 
and 206 amino acids respectively (Tischer et al., 1991 as cited by Bryne et al., 2005) 
(shown in figure 3). VEGF121 is freely secreted because of the absence of both exon 6 and 
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7. VEGF165 and VEGF145, are moderately bound as VEGF165, lacks only exon 6 whereas 
VEGF145 lacks exon 7.  VEGF189, and VEGF206 are tightly bound to the heparin residues 
due to the presence of exon 6 (Hoeben et al., 2004 as reviewed by Bao et al., 2009). Most 
recently identified is VEGF165b, which, unlike the other VEGF isoforms, is an 
angiogenesis inhibitor. VEGF165b differs from VEGF165 by the six amino acids in the 
carboxyl terminal (Woolard et al., 2004 as reviewed by Bryne et al., 2005). Of all the 
isoforms of VEGF, VEGF165 is the most abundant isoform with highest biological 
activity. 
1.6.2. VEGF receptors  
The binding of VEGF to a receptor depends on the isoform (figure 4). VEGF-A 
binds to both VEGFR-1 (Flt-1) and VEGFR-2 (KDR) (Bao et al., 2009) while VEGF-B 
shows high binding affinity to VEGFR-1.  VEGF-C and VEGF-D bind to VEGFR-3 and 
also induce tyrosine phosphorylation of VEGFR-2 and VEGFR-3 (Bryne et al., 2005). 
VEGF-E specifically binds to VEGFR-2 (Bryne et al., 2005). 
1.6.3. VEGF Signaling 
The binding affinity of VEGF to the VEGFR1 receptor is higher than to the 
VEGFR2 receptor, however the ability to induce tyrosine kinase activity is 10 fold higher 
in the VEGFR2 than the VEGFR1 receptor (Gille et al., 2001). VEGFR2 can induce 
phosphorylation of the ERK-1, ERK-2 and MAPK protein, whereas the VEGFR1 shows 
minimal expression of the phosphorylated ERK-2 (Figure 5). VEGF stimulates cell 
proliferation via Ras-Raf-MEK-ERK pathway.  VEGFR2 induces production of 
p38MAPK protein and aids in cell proliferation. (Bryne et al., 2005). Under stress 
conditions, the PI3-Kinase pathway (PI3K) and the Akt/protein kinase B (PKB) pathway  
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Figure 3: Isoforms of VEGF-A. 
Schematic representation of different isoforms of VEGF-A. 
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is activated by VEGFR2 to promote cell survival. VEGF also aids in cell migration via 
the focal adhesion kinase (FAK) and Paxillin, and by the phosphatidylinositol-3-
phosphate (PI3) Kinase/Akt pathway (Koch et al., 2012). 
1.6.4. VEGF as an angiogenic factor 
 VEGF acts as an important angiogenic factor and also aids in increasing vascular 
permeability in sites of tumors or chronic wounds. VEGFR1-/- deficient mice can die due 
to over production of endothelial cells and blood vessel formation, whereas VEGFR2-/- 
deficient mice can die due to lack of blood vessel formation, thus indicating that 
VEGFR2 positively regulates signal transduction while VEGFR1 negatively regulates it 
(Takahashi et al., 2005).  
1.7. Viral vectors for gene therapy 
Viral vector mediated gene therapy, using adenovirus, retrovirus, lentivirus, or 
adeno-associated virus (AAV), is one of the most efficient ways for delivering a gene of 
interest into the locale of wound and enhancing wound healing (Gauglitz et al., 2011).  
Viral vectors can be lytic or non-lytic depending on their ability to interact with the host 
cell. Lytic vectors break the host cell membrane to release virions as seen in adenovirus, 
adeno associated virus, and herpes simplex virus. Non-lytic viruses like retroviruses or 
lentiviruses keep the cell membrane intact after releasing its virions (Branski et al., 
2007). 
1.7.1. Retrovirus 
 Retroviruses are single stranded RNA viruses. Retroviral gene expression 
is long term and is mostly tissue specific, although retroviruses are capable of transducing  
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Figure 4: Binding of VEGF ligands to the VEGF receptors and 
their functions.  
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Figure 5: Signaling pathway of the VEGF activated by VEGFR2 
receptor 
VEGF activation by VEGFR2 regulates cell proliferation, cell migration, and 
cell survival.  
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In these recombinant viruses viral genes for replication and assembling are 
removed and a gene of interest is inserted into the viral vectors (Branski et al., 2009).  
only dividing cells with low efficiency (Anson et al., 2004). However, gene insertion 
through retroviruses is permanent as they integrate into the host cell chromosome and 
express the gene of interest. As a result, there are chances of non-specific integration into 
the chromosome, causing abnormal expression of the nearby host genes or insertional 
mutagenesis leading to expression of oncogenes (Yi et al., 2011).  
1.7.2. Adenovirus 
 Adenoviruses are double stranded DNA viruses being investigated for gene 
therapy. These are lytic viruses and have a genome size of 36kb. Adenoviral gene 
transduction is cell specific, stable, and can transduce both dividing and non-dividing 
cells (Branski et al., 2009). The viral genome does not integrate into the chromosome of 
the host cell, so transgene expression is transient (Silman et al., 2000). However, gene 
expression through adenovirus can cause an inflammatory response (Ritter et al., 2002).            
1.7.3. Adeno-associated virus  
Adeno-associated viruses (AAVs) are non-enveloped single stranded DNA 
viruses belonging to the Parvoviridae family. These are dependoviruses which usually 
depend on a helper virus like adenovirus or herpes simplex virus for a productive 
infection (Zhijian et al, 2006). AAVs can also infect cells and stay as a provirus in the 
absence of the helper virus. AAVs were discovered as a contaminant of an adenovirus 
isolate (Atchison RW, 1965). AAV is not very immunogenic and does not cause any 
known disease in humans (Samulski et al., 1987). 
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1.7.3.1. AAV Structure 
The viral capsid of AAV is about 25 nm in diameter and consists of 4.7 kbp of 
single stranded DNA flanked by 145 bp ITRs (inverted terminal repeats) on both ends. 
The ITRs are the cis-acting elements which are required for the packaging of the virus. 
The first 120 base pairs of the ITR is the palindromic region, which folds itself to 
increase base pairing and forms a T-shaped hairpin structure. The next 25 bp section 
called the D sequence is usually unpaired. AAVs consist of two ORF (open reading 
frames), the left ORF consisting of four replication proteins Rep78, Rep68, Rep52, and 
Rep40 that are always trans acting. Rep78 and Rep68 are produced from the p5 promoter 
from unspliced and spliced transcripts and are involved in DNA replication. These 
proteins are also involved in site-specific integration, nicking and positive/negative 
regulation of the AAV gene expression. The smaller replication proteins Rep52 and 
Rep40 from the p19 promoter are from unspliced and spliced transcripts, respectively, 
and are involved in the packaging of the DNA in the capsid. The other ORF, the right 
ORF, consists of the three capsid proteins (VP1, VP2 and VP3) produced by alternative 
splicing from the p40 promoter. The unspliced transcript forms the largest capsid protein 
VP1 (87 kDa). VP2 (72kDa) and VP3 (62kDa) are produced from the spliced transcript. 
These capsid proteins are present in a 1:1:10 molar ratio in the virion shell. (Daya et al., 
2008). 
1.7.3.2. AAV serotypes 
There are 9 serotypes of AAV named as AAV1 – 9, and over 100 additional 
isolates (Zincarelli et al., 2008). AAV1 – 6 were isolated as a contaminant of adenovirus 
in the lab, whereas the AAV7 – 9 were discovered by a novel PCR strategy where a 
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variable region of the capsid was analyzed to screen for isolates. AAV2, 3 and 5 are from 
humans, whereas AAV4 is from non-human primate. It is not known whether AAV1 is 
from a human or non-human primate as the neutralizing antibody for AAV1 is obtained 
from a monkey, but AAV1 was obtained from human tissue. AAV6 is considered to be a 
hybrid between AAV1 and AAV2, as the structure of the left ITR and the p5 promoter is 
similar to that of AAV2 while the remaining portions of the AAV6 is similar to AAV1 
(Wu et al, 2006).  
1.7.3.3. AAV Life cycle 
AAV can enter into lytic or lysogenic phases depending on the presence or absence of a 
helper virus, respectively (figure 6). Lysogenic infection takes place in the absence of a 
helper virus and the AAV gene expression is repressed. Wild type AAV then latently 
integrates into chromosome 19 by site specific integration with the help of cis acting ITR, 
Rep78 or Rep68 and 138 bp integration efficiency element (IEE) or 16 bp Rep binding 
element (RBE) present in the p5 promoter (Daya et al., 2008).  Latent AAV infection is 
nonpathogenic because of the negative feedback regulation of the Rep proteins. Site 
specific integration of the AAV potentially makes safe and stable transgene expression; 
however, as the Rep and Cap sequences are deleted from recombinant AAV, very little 
integration is observed (Goncalves, 2005). 
In the presence of the helper virus (adenovirus or HSV), the AAV genome enters 
into lytic infection phase and replicates, producing virions and expressing genes of 
interest. Adenovirus provides E1a, E1b, E2a, E4, and VA RNA helper genes to facilitate 
infection. E1a functions as a trans-activator, regulating activity of Ad genes and Rep and 
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Cap genes. E1b and E4 function together in transport of mRNA, and E2a along 
with VA RNA facilitates and stabilizes AAV mRNA translation. (Coura et al., 2008). 
HSV mediates infection via DNA polymerase and helicase activity (Daya et al., 2008). 
Lytic infection can also be initiated in the absence of the helper virus via inhibitors or 
DNA damaging agents like UV radiation. However, his process of induction is not 
efficient (Golcalves et al., 2005). 
1.7.3.4. AAV tissue tropism 
The efficiency of AAV transduction in tissues varies from serotype to serotype. AAV1 is 
very efficient in transducing skeletal muscles. AAV2 can transduce the liver, kidney, 
skeletal muscle, and central nervous system (CNS). AAV4 can transduce specific cell 
types in CNS like ependyma and astrocytes, as well as retinal pigmented epithelium 
(RPE) optimally. AAV5 is efficient in transducing CNS, RPE and photoreceptor cells. 
AAV6 transduces skeletal muscle and liver with a higher efficiency than AAV1 and 
AAV2. AAV7 transduces skeletal muscles with very high efficiency. AAV8 can 
efficiently transduce wide range of tissues like the liver, skeletal muscle, pancreas, 
diaphragm, and cardiac muscle. Tissue specificity for AAV9 is similar to AAV2, but 
AAV9 transduces tissues with much higher efficiency. (Wu et al., 2006). 
1.7.3.5. Recombinant AAV as a gene therapy vector 
AAV is one of the ideal gene therapy vectors because of its ability to target the 
tissue and express the gene of interest. Depending on the tissue and cellular replication, 
expression can be long term (e.g. muscle) or for a limited period of time being degraded 
over time (e.g. liver). Due to the lack of the Rep and Cap gene and the cis acting IEE, 
AAV does not integrate into the chromosome; as a result it is nontoxic to the cells and 
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Figure 6: Life cycle of AAV 
Lytic or lysogenic life cycle of AAV depending on the presence or absence of 
helper adenovirus. In the presence of a helper virus, AAV genome 
replication, gene expression and packaging, and release of virus takes place. 
When the helper virus is absent, AAV integrates into chromosome 9. The 
integrated AAV is then rescued and undergoes replication upon 
superinfection of adenovirus.  
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tissues (Daya et al., 2008). Recombinant AAV is made by designing the AAV vector 
with the promoter region, the gene of interest, and flanked by 145 bp ITR on both sides.  
For efficient packaging of the AAV vector, the size of the promoter and the gene of 
interest is generally between 4.1 to 4.9 kb. Packaging becomes less efficient when the 
size of vectors exceeds 5 kb. (Pacak et al., 2011). The plasmid vector is then co-
transfected with the helper plasmid containing the Rep and Cap genes and the adenovirus 
gene of interest in mammalian cells. The recombinant AAV genome is then released from 
the AAV plasmid and undergoes transcription. Rep 78 and Rep 68 participate in 
accumulating the replicates, and Rep 52 and Rep 40 are involved in the packaging of the 
single stranded replicates into the viral capsid formed by VP1, VP2 and VP3 (Golcalves, 
2005). The recombinant virions are then released from the cells along with the Ad 
particles. Due to the difference in density and temperature sensitivity between the Ad 
particles and the rAAV virions, the Ad particles are removed by heat inactivation at 56°C 
and isopycnic cesium chloride density ultracentrifugation. 
The efficiency with which the rAAV can transduce tissue or cells depends on 
binding and entry of AAV into the cell, viral trafficking, entry into the nucleus, uncoating 
of capsid to release single stranded AAV, and finally synthesis of double stranded DNA. 
Each of these steps can act as a rate limiting step in gene expression (Daya et al., 2008). 
Thus, to enhance AAV gene expression, trans-splicing AAVs have been designed. These 
trans-splicing AAV form head to tail concatemers by recombination of AAV ITR, and 
can deliver genes up to 9 kb in size (Yan et al., 2000). Another category of the AAV is 
the self-complementary AAV (scAAV) which is designed specifically to reduce the lag 
phase time required for second strand synthesis. These scAAV can fold to synthesize the 
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second strand. However, a disadvantage of scAAV is that the transgene size is reduced to 
less than 3kb (Wu et al., 2006) 
Thus, AAV because of its non-immunogenic and non-pathogenic nature and its 
wide tissue tropism is a prime vector for gene modification (Coura et al., 2008). 
1.8. Red light therapy 
Red light therapy was discovered long ago in 1960, but only recently is it being 
widely used in nerve and tissue regeneration, wound healing, reduction in pain and 
inflammation (Avci et al., 2014). It uses a red light (670 nm) laser or red light emitting 
diodes (LED) or a combination of both to promote bio-stimulatory effects on cellular, 
molecular and tissue level (Amid et al., 2013). In vitro studies have shown better 
survivability and viability of ASCs, and increased level of growth factor secretion by 
ASCs with exposure to red light (Kim et al., 2012).  
1.8.1. Mechanism of action 
The mechanism by which red light therapy functions is not known, but it appears 
that the absorption of red light by photo-acceptors in the plasma membrane of cells and 
cytochrome C oxidase, a mitochondrial chromophore, leads to photo dissociation of nitric 
oxide thereby causing an increase in energy level, mitochondrial activity, electron 
transport, ATP production. It also positively regulates the activity of transcription factors 
involved with cell migration, cell proliferation, cell adhesion (Avci et al., 2013). 
1.8.2. Secretion of growth factors and cytokines upon red light exposure 
 Exposure of damaged skin tissue to red light leads to an increased 
secretion of fibroblast growth factor (FGF), platelet derived growth factor (PDGF), 
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vascular endothelial growth factor (VEGF), transforming growth factor β (TGF-β1), IL-
1β, TNF-α, and increased mRNA level of ICAM-1, connexin 43 (Cx43), and decreased 
secretion of IL-6. Secretion of IL-1β, TNF-α in the damaged site recruits matrix 
metalloproteinases (MMP) to remove the damaged collagen fibers and synthesize new 
fibers.  Later, tissue inhibitors of metalloproteinases (TIPMs) further protect the newly 
formed collagen fibers by inhibiting MMPs. Cx43 then enhances cell to cell 
communication between dermal fibroblasts and further enhances collagen production.  
1.8.3. Concern with red light therapy 
 Red light therapy is also highly dose dependent. Low dose of red light results in 
inefficient healing and high level exposure can lead to the damage of tissue. Thus the 
correct dosimetry parameter has to be known to perform such therapy (Avci et al., 2012). 
1.9. Hypothesis, Objective and Specific Aims of this thesis 
 The inability to heal wounds, leading to chronic wounds, is a growing problem in 
our society and new treatments are needed. The overall hypothesis is that adipose derived 
stem cells (ASCs) expressing VEGF-165, via delivery by an AAV-VEGF-165 vector, 
will neutralize the chronic wound environment and enhance neovascularization and 
wound closure in an in vitro 3D wound culture. Also exposure to red light (670nm) will 
enhance wound closure. 
The overall objective of this thesis is to develop an organotypic wound model to 
study chronic wound healing and test therapeutic strategies to close the wound using (1) 
ASCs expressing VEGF-165, via delivery by an AAV-VEGF-165 vector, or (2) red light 
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therapies, which are predicted to neutralize the chronic wound environment, enhance 
neovascularization, and facilitate wound closure. 
To achieve these objectives, I have proposed three specific aims. 
Aim 1:  
Develop a 3D organotypic human skin wound model system. 
Aim 2:  
Construct and test AAV-VEGF transduction in ASCs and test the efficiency of ASCs 
transduced with AAV-VEGF to induce the closure of wounds in a 3D organotypic human 
skin wound model system. 
Aim 3:  
Determine the effect of red light on cell growth and wound healing. 
 Together this work will provide new insights into the mechanisms that prevent 
wound healing, provide a novel way to test potential therapies, and offer improvements to 
current stem cell therapy approaches.   
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Chapter 2: Material and Methods 
2.1. Isolation and culture of ASCs 
Adipose derived stem cells (ASCs) were isolated from lipectomy or lipoaspirate 
specimens under the IRB protocol from the Miami Valley Hospital. The specimens were 
washed three times with PBS and digested with Collagenase I and incubated at 37ºC for 
30 minutes with gentle mixing every 2 minutes  to separate out the stromal vascular 
fraction (SVF) which contains ASCs. Next the specimens were centrifuged at 1200 x g 
for 10 minutes. The supernatant was discarded and the cellular pellet was re-suspended in 
ASC medium (Dulbecco’s modified Eagles medium, 10% fetal calf serum, 1% Antibiotic 
Antimycotic Solution). Cells were counted and seeded at a density of 105 /ml cells in T75 
flasks. Medium was changed the next day to remove the non-adherent cells. The cells 
were maintained at 37ºC and 5% CO2 and medium was changed every alternate day.  
Upon 90% confluence, the cells were detached using TrypLE and underwent 3 rounds of 
passaging at 1:2 dilution before experiments. The viability of the cells was tested via a 
trypan blue assay and was routinely 80-95% alive. 
2.2. Characterization of ASCs 
The ASCs were characterized according to the International Federation for 
Adipose Therapeutics and Science (IFATS) and the International Society for Cellular 
Therapy (ISCT) standard by an immunofluorescence multicolor flow cytometry strategy 
(Accuri C4, BD Biosciences, San Jose, CA). The positive stem cell markers were APC 
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anti-human CD13, CD34, CD36, CD73, CD90 and CD105 and the negative stem cell 
markers were PE anti-human CD31, PE anti-human CD45 and APC anti-human CD106 
(BioLegend (San Diego, CA)). Cells were seeded in 6 well plates at a density of 104 
cells/well and were subsequently detached using TypLE, spun down and reconstituted in 
PBS and 10% FCS. After conducting a cell count, the cells were equally distributed in 
each tube and mixed with the appropriate stem cells marker antibodies and incubated for 
25-30 minutes. The cells were then washed with PBS and spun down. This washing 
process was repeated three times and the cells were re-suspended in PBS with 10% FCS. 
The cells were then characterized by flow cytometry under the FL1, FL2 and FL4 
channels. 
2.3. Development of organotypic human skin wound models 
The skin cultures were obtained under an IRB approved protocol by collaborators 
at the Miami Valley Hospital. The wounds were created by punch biopsy from 
abdominoplasty and brachioplasty skin fat specimens. Full thickness 2 or 3 mm punches 
extending from the epidermis into the fat were made in the center of the 8 mm skin flaps. 
These wound models were maintained in the central chamber of a Millicell® (EMD 
Millipore, Billerica, MA) hanging from the sides, without touching the bottom of the 
well. This created an air-liquid interface for the skin cultures in the millicell where the 
bottom part of the wound was exposed to the medium, in the well and the top part was 
exposed to air. The wound models were fed with the ASC medium (DMEM-F12, 10% 
FCS and 1% ABAM). Medium in the wells was changed every 48 hours.  Survival of the 
wound model system was tested periodically by MTT assay. 
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2.4. MTT viability assay on skin model 
Test wound model (supplemented with ASC medium) and control wound model 
(fixed in 4% paraformaldehyde for 2 hours) were used to study the viability of the tissue. 
The wound models were washed with PBS, and then 100µl of MTT in 1:10 dilution was 
added to the base of the transwell containing the wound models and incubated at 37ºC for 
four hours in the dark. After 4 hours, the wound models were observed for purple color 
formation and imaged under the microscope. 
2.5. Infusion cloning 
In an Eppendorf tube, 1.5 µl of the VEGF gene (100 ng) synthesized by 
Integrated DNA Technology was incubated with 1 µl of the linearized AAV5-CMV-
IRES-GFP or AAV5-CAG-IRES-GFP plasmid along with 2 µl of the 5 X Infusion 
enzymes and 5.5 µl of water for 15 minutes at 50ºC and was then kept on ice. After 
cooling, 2.5 µl of the above reaction mix was incubated with Stable competent cells on 
ice for 15 minutes. The mixture was then heat shocked for 55 seconds at 42°C and cooled 
on ice for 5 minutes. Next 250µl of SOC medium was added to the mixture and placed on 
a shaker for 1.5 hours and then plated on Ampicillin and Gentamicin/Ampicillin plates 
and incubated overnight at 37ºC for colony formation. 
2.6. Restriction Digestion 
In an Eppendorf tube, 1.5 µg of the plasmids were mixed with 1.5 µl of the 
specified restriction enzyme(s), 2 µl of buffer, 2 µl of 1 X BSA and water.  This solution 
was then incubated at 37ºC for 1.5 – 2 hours. For double digestions, the plasmids were 
digested with SalI and BamHI and for single digestion, the plasmids were digested with 
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MscI or XmaI. To evaluate digestion, a 10 µl volume of both the digested plasmids and 
the undigested plasmids were run on a 1.2% agarose gel for 30 mins at 120 V.  
2.7. Plasmid DNA extraction 
A single colony was grown in 5 ml of LB broth with Ampicillin overnight at 37°C. After 
24 hours, 4 ml of the grown culture was transferred to a 250 ml LB broth and grown 
overnight at 37ºC. Next day the culture was centrifuged at 10,000 rpm for 5 minutes. The 
supernatant was aspirated and the pellet was re-suspended in 7ml of Buffer PR1 and 
mixed well. Next 7 ml of Buffer PL2 was added and gently inverted 5 – 6 times to ensure 
mixing and was incubated for 5 minutes at room temp. After 5 minutes, 7 ml of buffer 
PN4 was added and the solution was mixed by gently inverting the flask 10 times. After 
10 minutes of incubation at room temperature, the solution was centrifuged at 10,000 X g 
for 25 minutes. The lysate was transferred into a Perfect Prep Endofree filter and the 
filtrate was collected in a fresh tube. 0.3 volume of isopropanol was added to the filtrate 
and mixed well by inverting the tube, for 5 – 6 times The isopropanol lysate mixture was 
added to the Perfect Prep Endofree column (equilibrated with 2.5 ml of Buffer BL and 
centrifuged for one minute) and centrifuged at 10,000 X g for 2 minutes. The flow 
through was discarded and 10 ml of buffer PW was added to the column and centrifuged 
at 10,000 X g for 2 minutes. This step was repeated again. Next 3 ml of absolute ethanol 
was added to the column and centrifuged at 10,000 X g for 2 minutes. The flow through 
was discarded and the column was centrifuged again at 10,000 X g for 5 minutes to 
remove the excess alcohol. The column was set to air dry. To elute DNA, 1 ml of Buffer 
PEB was added to the center of the membrane and incubated for 5 minutes. A fresh 
collection tube was used and the DNA was collected and stored at -20ºC for future use. 
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2.8. Transfection of ASCs with AAV plasmid 
6.5x104 cells/cm2 were seeded in a 24 well plate 24 hours before transfection. 
After 24 hours, 0.5 µg of plasmid DNA was diluted in 25 µl of DMEM high glucose and 
1.5 ul of the transfection reagent was diluted in 25 µl of DMEM high glucose. The 
diluted transfection reagent was added to the diluted plasmid DNA and mixed well. The 
transfection complex was incubated at room temperature for 15 minutes. Post incubation, 
the medium in the wells was replaced with fresh medium and the transfection complex 
was added dropwise to the well and incubated at 37ºC. The medium was replaced with 
fresh medium the next day and the transfection efficiency was measured by comparing 
the number of GFP positive green fluorescent cells with the amount of non-transfected 
cells 24 hours post transfection.  
2.9. VEGF ELISA 
VEGF ELISA assay was performed on medium collected on day 3 from 
transduced and non-transduced cells by the VEGF ELISA kit (DY293B, R&D system). 
100 µl of MαH capture antibody at a concentration of 1 µg/ml was added to the wells the 
previous night and sealed and kept overnight at room temperature. After 18 hours of 
incubation, the wells were washed with 400 µl of wash buffer three times and 300 µl of 
reagent diluent was added to the wells and incubated at room temperature for one hour. 
After one hour of incubation, the wells were washed with 400 µl of wash buffer; this 
washing step was repeated two subsequent times. In triplicates, dilutions of 2000 pg/ml - 
31.25 pg/ml of human VEGF standard and medium from transduced and non-transduced 
cells were added to the wells and incubated for another two hours at room temperature 
after which the wells were washed with wash buffer as in the previous steps. Next 100 µl 
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of biotinylated GαH VEGF detection antibody were added to the wells and incubated at 
room temperature for two hours. After the incubation period, the wells were washed with 
100 µl of Streptavidin HRP and incubated in the dark for 20 minutes and then washed 
with wash buffer. Next 100 µl of substrate solution were added to the wells and kept in 
the dark for 20 minutes for color development. Post color development, 50 µl of stop 
solution was added to the wells and the plate was read at 450 nm with wavelength 
correction at 540 nm.  
2.10. Production of recombinant AAV5 
AAV5-CAG-VEGF-IRES-GFP virus was made by cis acting and trans-acting 
Baculovirus vectors containing the AAV plasmid with the gene of interest flanked by 
ITR and the rep and cap genes.  These vector viruses, along with the helper adenovirus, 
were provided by the University of Iowa Viral Vector Core.  Together; these viruses were 
infected into SF-9 insect cells to obtain the desired AAV5-CAG-VEGF-IRES-GFP virus 
with a viral titer of 3.7x1012 vg/ml (batch 1), 9.11x1012 vg/ml (batch 2), 6.63x1012 vg/ml 
(batch 3). AAV5-CMV–IRES-GFP (2.5x1014 vg/ml) virus was used as a control virus 
during subsequent experiments. 
2.11. Transduction of ASCs with AAV vectors 
6.5x104 ASCs were transduced with rAAV5-CAG-VEGF-IRES-GFP and AAV5-
CMV-IRES-GFP virus (control) at a MOI of 106 vg/cell in combination with 0.5 µM/ml 
Hoechst 33342 in ASC medium in Eppendorf tubes and incubated at 37ºC for one hour. 
After one hour, the cells were seeded in a 48 well plate. Medium was changed the 
following day to remove non-adherent cells. Non-transduced ASCs were used as a 
negative control. Two days after transduction, the cells were viewed under fluorescence 
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microscopy to observe green fluorescent cells. Medium collected from the cells after 
three days was used for VEGF ELISA. 
2.12. Transduction of ASCs with Ad-VEGF and Ad-GFP 
1x105 ASCs were transduced with Ad-CMV-VEGF or Ad-CMV-GFP at a MOI 
of 100 pfu/ml in Eppendorf tubes and incubated at 37ºC for one hour. After one hour, the 
cells were centrifuged at the supernatant was discarded. The pellet was resuspended in 
ASC medium and seeded in a 24 well plate. Medium was changed the following day to 
remove non-adherent cells. Non-transduced ASCs were used as a negative control. Two 
days after transduction, the cells were viewed under fluorescence microscopy to observe 
green fluorescent cells. Medium collected from the cells after three days was used for 
VEGF ELISA. 
2.13. Wound healing experiment on punch biopsies 
24 wound models treated with ASC-AAV5-CAG-VEGF-GFP, ASC-AAV5-
CMV-GFP, non-transduced ASCs, or ASC medium (n=8) were assessed for wound 
healing by measuring  the area of the wound punch every alternate day using ImageJ and 
Picture frame software. Rate of wound closure was determined by comparing the present 
size of the wound to the original wound area before treatment. Comparison between each 
group was made to assess the rate of healing conferred by each experimental group. 
2.14. Cryo-OCT sectioning 
Full thickness unfixed biopsies were frozen at -80ºC with tissue freezing medium 
in a suitable mold. When frozen, 15 µm thick sections were cut using cryostat at -27ºC. 
The sections were then transferred to microscope slides by gently touching the tissues to 
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the slide; the slides were labelled according to their respective tissue sample and stored at 
4ºC. 
2.15. Paraffin embedded sectioning 
The tissues were fixed in 4% PFA (paraformaldehyde) or 3.7% formaldehyde for 
2 hours after which the fixative was poured off and rinsed with 50% ethanol. 
Immediately the tissues were put in fresh 50% ethanol for one hour with 2 changes in 
between for 20 minutes each. Next the tissues were dehydrated in 70% ethanol, 95% 
ethanol and 100% ethanol for 1 hour each. After the dehydration steps, the tissues were 
cleared in xylene for one hour.  During this, the xylene was replaced once every 20 
minutes. The tissue were then infiltrated with equal volumes of xylene and molten 
paraffin for one hour at 60ºC. After one hour, the xylene/paraffin mix was replaced with 
molten paraffin and the tissues were infiltrated for three 30 minute washes. The tissues 
were then transferred with clean and pre-warmed forceps into their proper molds. For the 
future identification of tissues, embedding rings were placed on the molds and labelled 
accordingly. The molds were filled with molten paraffin and were allowed to set on a 
cold plate. Once solidified, the wax blocks containing the tissues were removed from the 
molds and 10 µm sections were made using a microtome. After sectioning, the ribbons 
were placed in a water bath at 48ºC and then were transferred to clean microscopic slides 
and were kept at 55ºC for 24 hours. The next day the slides were taken out and cooled at 
room temperature and were used for staining or were stored at 4ºC for future use. 
2.16. Hematoxylin and Eosin (H&E) staining 
The sections on microscopic slides were fixed in alcoholic formalin (40% 
formaldehyde and 95% ethanol) for one minute and then washed first in tap water 
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followed by distilled water. The sections were then stained with hematoxylin for 15 
minutes followed by a rinse in tap water and then dipped in bluing reagent for 30 
seconds. The sections were again washed in tap water and dipped in eosin for 5 minutes. 
Next, the sections were washed in 95% alcohol for 2 times, followed by 3 washes in 
100% alcohol, and then 2 final washes in xylene. The sections were then mounted with 
Permount and cover-slipped and sealed along the slides with nail polish. The slides were 
viewed under the microscope immediately or stored at 4ºC. 
2.17. Immunofluorescence staining 
Cryo-OCT sectioned samples were first fixed with 3.7% formaldehyde in PBS for 
15 minutes, followed by 3 rinses with PBS. Next the sections were blocked with blocking 
buffer (9.5 mL 10 X PBS, 0.5 mL normal goat serum and 30 µL Triton X-100 (100%) for 
one hour.  The blocking buffer was then aspirated and diluted primary antibody (Mouse 
mAb CD31, Cell Signaling Technology, Inc., #3548, 1:3200 dilution; Mouse mAb Ki-67 
Cell Signaling Technology, Inc., #9449, 1:800 dilution) at the required concentration was 
poured over the sections, which were then incubated overnight at 4ºC. The next day the 
sections were rinsed in PBS for three minutes. To minimize background, during the 3rd 
rinse, high salt PBS (50 mL 1 X PBS, 1.169 g NaCl) was used. Next, the sections were 
incubated in fluorochrome conjugated secondary antibody (goat anti-mouse Alexa 
Fluor® 488; goat anti-mouse Alexa Fluor® 568, Invitrogen)  diluted in antibody dilution 
buffer (20 mL 1 X PBS, 0.08 g BSA, 60 µL 100% Triton X-100) for 1-2 hours in the 
dark and then rinsed with PBS for three times. The sections were finally cover slipped 
and sealed along the sides with nail polish. The slides were immediately viewed under 
the microscope or stored at 4ºC 
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2.18. Wound healing assay on cells 
Wound healing assays were performed on monolayers of ASCs by creating a 
scratch in the cell culture with the help of a pipette tip. Cell debris was removed by 
washing with PBS and then replaced with medium. Scratches were created on both 
transduced and non-transduced cells to compare the healing rate. Cells were observed 
under the microscope over a period of days to determine the number of days required for 
the scratch to heal.  
2.19. Red light exposure on ASCs 
ASCs were seeded at 1x105 cells per well in a 12 well plate. After two days, the 
cells were exposed to red light, green light or ambient light (control) for 15 minutes and 
were kept for 48 hours incubation at 37°C. Cells exposed to red, green or ambient light 
were counted two days after exposure and the count was compared to the number of cells 
seeded and the count before exposure to red or green LED light or ambient light to study 
the effect of light exposure on ASCs. 
2.20. Red light exposure on wounds 
1.5 mm2 wound models were exposed to red light or ambient light for 15 minutes 
every other day for 20 days. Measurements on the wounds were taken throughout the 
experiment to study the effect of red light exposure on inducing wound closure. 
2.21. Statistical analysis 
 All of our data are expressed as mean ± S.D. Statistical analysis was done using 
GraphPad Prism.  Two way ANOVA followed by Bonferroni test was used to find 
significant differences. p value < 0.05 was considered significant.
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Chapter 3: Organotypic wound model 
3.1. Rationale 
Chronic wound healing is a complex process. Most of the studies for the treatment 
of chronic wounds have been performed on mice models which are physiologically and 
hormonally different from humans. Often studies in mice cannot be replicated in humans, 
and are thus an inadequate chronic wound model system, creating a major barrier to 
understanding the mechanism of wound healing in humans (Nuutila et al., 2014). We 
proposed to develop a novel organotypic multidimensional wound model culture system 
that will replicate the complex tissue environment of human wound in vivo and thus help 
in developing a therapeutic approach that will accelerate the healing of a wound. 
Previous studies in our lab showed that the skin biopsies do not retain the 
structure if maintained in a well plate without a support. We hypothesized that skin 
biopsies would retain their structure if held in a container that would allow growth at the 
air-liquid interface. Moreover, we hypothesized that a smaller biopsy in the center of the 
larger biopsy would act as a wound and recapitulate wound healing in humans. 
Organotypic human skin cultures with a central 2mm or 3mm wound were used as the 
wound models. The skin cultures were obtained under an approved IRB protocol by 
collaborators at the Miami Valley Hospital. The structure of the wound was analyzed in 
paraffin embedded sections or Tissue Freezing Medium embedded cryostat sections. 
Histological analyses of the wound sections were performed after hematoxylin and eosin 
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staining. Expression of the endothelial cell marker and proliferative cells were examined 
by immunofluorescence assay with CD31 and Ki-67 antibody, respectively.  
3.2. Results 
3.2.1. Histoarchitecture of the wound 
To study the structure of the wound model, cryo-OCT embedded sections of the 
wound models were stained with Hematoxylin and Eosin (H&E). H&E imaging revealed 
the structure of the wound models, showing the epidermis, dermis and the subcutaneous 
fat and their sublayers. Figure 7a shows an example of a wound model in culture and 
figure 7b the sublayers of the epidermis, with the disrupted stratum corneum on the 
topmost layer, followed by stratum granulosum, the prickle layer stratum spinosum and 
the bottommost layer stratum basale separating the epidermis and dermis. Wound models 
were created from three tissue types: abdominoplasty, brachioplasty, and panniculectomy 
(figure 8).  For the biopsies to be considered healthy, we examined into criteria like 
survivability of wound, maintenance of structure and integrity of wound in the millicells, 
normal anatomy of the skin layers.  
Immunostaining of the wounds with CD31 and Ki-67 demonstrated staining of a few 
cells within the dermis layer of the wound model. Ki-67 stained cells were observed in 
the epidermis layer (figure 9). Positive staining for CD31 shows that the tissues were 
positive for endothelial cells indicating the presence of some blood vessels. Positive 
staining for mitotically active Ki67 shows that the tissues were positive for proliferative 
cells indicating that few cells were replicating in this model system. Control staining 
(with no primary antibody but only secondary antibody) showed no staining for Ki67 or  
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Figure 7: Architecture of the organotypic wound model system. 
(a) Two month old multidimensional wound model with 8mm outer ring 
diameter and 2 mm inner punch (wound). Image taken at 0.63X 
magnification.  (b) H&E staining of two month old the 2 mm wound model 
showing epidermis and dermis along with the sublayers. SC - Stratum 
Corneum, SS - Stratum Spinosum, SG - Stratum granulosum, SB - Stratum 
Basale, DR - Dermal ridges, E - Epidermis and D - Dermis. Images taken at 
4X magnification. 
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Figure 8: H&E staining of organotypic wound model 
H&E staining of (a) one month old 3 mm brachioplasty partial thickness 
wound, (b) one month old 3 mm panniculectomy wound. Images taken at 4X 
magnification. (c) 10X magnified epidermis and dermis layer of a month old 3 
mm panniculectomy wound.  
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Figure 9: Immuno-characterization of wounds 
Immunostaining on 2 months old 2mm wound model with (a) Ki67 antibody (in red) 
staining proliferative cells, (b) CD31 antibody (in red) staining blood vessels. Nucleus 
(DAPI) staining in blue. Images taken at 4X magnification. 
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CD31. Together these data suggest that the wound models were viable long term.  
3.2.2. Viability of wound model:  
Viability of two month old wound model was tested by MTT assay (figure 10) 
and evidenced by the formation of the purple color within 1 hour of addition of MTT into 
the wound bed. By contrast, a 4% paraformaldehyde (PFA) fixed wound did not develop 
color even after 6 hours of MTT addition, indicating that the PFA fixed wound model 
was dead.  The wounds treated with MTT retained the purple color even after 6 hours of 
MTT addition (as shown in figure 10). 
Similarly, a MTT assay was re-performed on four month old wound models 
previously studied for viability when the wound was 2 months old (figure 11). The 
minced tissue showed that within 1 hour of MTT addition, purple color darkened and it 
retained strong purple color till 3 days post-staining indicating that the wound model was 
viable after 4 months. 
3.3. Discussion 
In this study, we used organotypic human skin biopsies obtained by brachioplasty, 
abdominoplasty, and panniculectomy, as wound models.  These models were maintained 
in millicells which provided them with sufficient support to maintain the structural 
integrity of the skin and wound. The wound models in the millicells were maintained at 
an air liquid. We expected that the wound models would require some additional growth 
factor like EGF or FGF or additional medium like F medium supplemented with 
hydrocortisone for survival of the wounds. However, it was observed that ASC medium 
by itself was sufficient enough to provide nutrients for survivability of wounds.  
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Figure 10: MTT assay to study viability of wound 
MTT assay demonstrates viability of 2 month old unfixed wound model (a-c) 
and not 4% paraformaldehyde fixed (d-f). (a) Within 1 hour after addition of 
MTT to the wound a purple color began to develop in unfixed wound models 
and continued to intensify (b) after 2 hours and (c) after 6 hours indicating 
that the unfixed wounds are still viable after 6 hours of MTT addition. By 
contrast, no purple color formation was observed in 4% paraformaldehyde 
fixed wounds at (d) 1 hour, (e) 2 hours, or (f) 6 hours after MTT addition 
indicating that the fixed wounds are dead. Images taken at 1.25X 
magnification. 
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Figure 11: Viable 4 month old wound model 
MTT assay re-performed on 4 month old minced wound model showed that 
the skin tissue and wound model is still viable. (a) at 0 hour after addition of 
MTT to the wound , (b) after 2 hours, (c) after 1 day and (d) after 3 days of 
MTT addition.   
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It was confirmed by MTT assay that the wound models were viable for at least 
four months as seen by the purple color formation in live wounds. The formation of the 
purple color in the live wounds was due to the breakdown of the MTT into formazan 
which indicates active metabolism in the live wound whereas in the control wounds fixed 
with paraformaldehyde, no color change was observed because the cells lost their ability 
to convert MTT into formazan, indicating that the wounds were not viable. 
Measurements taken on the wound models showed that the wounded area did not close 
by itself even after three months indicating that these wounds were chronic and could not 
heal naturally and would need additional therapies for healing.  
Interestingly, these wound models derived from the skin are expected to be have a 
microbiome. Although we expected the antibiotics and antimycotics (ABAM) to kill the 
microbiome we periodically would get contamination of the medium. When the wounds 
were swabbed on to an agar plate in the absence of the antibiotics, bacterial colony 
formation was observed within 24 hours (data not shown). However, when the medium in 
contact with the basolateral side of the wound was plated on the antibiotic free agar 
plates, no colony formation was observed (data not shown) thus suggesting that the 
bacterial colony formation seen on the agar plate was due to the bacteria present on the 
skin surface of the punch biopsies. It is possible that the bacteria in the skin of the 
wounds are beneficial bacteria necessary for the survival of the skin. Despite the presence 
of bacteria, the wound cultures remained viable. Future work will explore this finding 
further.  
H&E staining performed on the wound models confirmed the anatomy of skin 
model.  A disrupted epidermis was observed in the wounded tissues (Figures 7, 8). It was 
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also observed that the epidermis of the wounds obtained from brachioplasty had a thinner 
epidermis than that of the abdominoplasty. Also biopsies obtained by abdominoplasty 
had a thicker subcutaneous fat layer than brachioplasty biopsies. The full thickness 
abdominoplasty wound models appears to be a better model for studying wound healing. 
Immunostaining performed on the wounds with Ki67 antibody confirmed 
presence of mitotically active cells. CD31 staining on the wounded tissues showed a few 
blood vessels in the dermis region. It is expected that with the healing of the wounded 
tissues with VEGF treatment, more blood vessels would develop providing more of 
oxygen and nutrients to wound to enhance healing. However, in our models, there does 
not seem to be a large number of blood vessels. This could be due to the static nature of 
the medium (no blood flow) or insufficient cytokines to stimulate new blood vessel 
formation, or both. Few cytokeratin positive cells were found in the epidermis region of 
the wound models indicating the presence of few keratinocytes in the epidermis of the 
skin. 
Most of the studies for wound healing are being performed in mouse models. Studies 
in mice cannot be replicated in human as mice genetically, hormonally, physiologically 
differ from human. Skin equivalents made from layering epidermis and dermis on a 
collagen matrix is also being studied as a model. The disadvantage of the skin equivalents 
is that often when epidermis stratifies, the stratum corneum spinosum layer is not formed 
and the statum corneum layer becomes too thin, as a result the tensile strength of these 
skin equivalents diminish (Sauto et al., 2009). Overall, this human skin model we 
developed can be used to study wound healing as these models anatomically represent 
human skin. 
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Chapter 4: Adipose derived stem cells potentiate wound 
healing 
4.1. Rationale 
Chronic wounds have become a major problem in our society (Sen et al., 2009). 
Potential treatments for chronic wounds are hyperbaric oxygen treatment, flap surgery, or 
amputation but these do not give a permanent solution. Thus efficient, accelerated, less 
invasive, personalized treatments have to be developed for millions suffering from 
chronic wounds. We expected to develop a cell and gene based therapy using adipose 
derived stem cells (ASCs) and vascular endothelial growth factor (VEGF) for treating 
chronic wounds. ASCs, through their regenerative properties, induce wound healing 
when transplanted into the wound bed. However, ASCs by themselves are not enough for 
the treatment of a chronic wound. We are developing a novel therapeutic strategy using 
an AAV to transfect the VEGF gene into ASCs in order to enhance VEGF expression to 
promote wound healing. We hypothesize that these VEGF expressing ASCs should then 
neutralize the chronic wound environment, enhance neovascularization and induce 
wound closure. I tested this hypothesis using in the organotypic in vitro wound model 
describe in Chapter 3.  
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4.2. Results 
4.2.1. Construction of recombinant AAV 
The construct for expressing VEGF-165 was designed by “Snapgene” software to 
include a chimeric synthetic intron upstream of the Kozak consensus start sequence, a 
VEGF-165 open reading frame (ORF), and a 3’ poly-A sequence, all flanked by NheI and 
EcoRI restriction sites. The VEGF-165 gene block was synthesized by Integrated DNA 
Technology.  The VEGF-165 gene was successfully cloned into the multiple cloning site 
(MCS) of the two AAV backbone pAAV-CMV-GFP and pAAV-CAG-GFP (figure 12). 
Both of these plasmids contained a GFP gene marker that is produced independently of 
the VEGF-165 protein by virtue of an internal ribosomal entry site separating the two 
genes. Ampicillin resistant colonies were grown and purified plasmid DNA was obtained 
by an Endofree plasmid maxi kit (5 Prime).  Digestion of the plasmids with SalI and 
BamHI resulted in the release of the VEGF gene at around 0.9kb, which is in agreement 
with the expected size of the VEGF gene, 874bp. Digestion of the plasmids with MscI 
and XmaI showed the expected bands (as indicated by the arrows in figure 13) for 
pAAV-CAG-VEGF-GFP plasmid at 1033bp, 1288bp, 2471bp, 3503bp for MscI digestion 
and 11bp, 1685bp , 1947bp , 4652bp for XmaI digestion, but not for pAAV-CMV-
VEGF-GFP. pAAV-CMV-VEGF-GFP showed some additional, unexpected, bands and 
was missing some of the predicted bands indicating that the ITRs were damaged.  
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Figure 12: Cloning of VEGF into AAV plasmid 
Figure represents the process for cloning the VEGF gene block into the 
multiple cloning site (MCS) region of AAV plasmids by Infusion cloning and 
production of  AAV-VEGF plasmid. Different parts of the AAV plasmid are 
highlighted in different colors. 
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Figure 13: Restriction digestion of VEGF cloned AAV plasmid 
Digestion of the (a) pFB-AAV-CAG-VEGF-IRES-eGFP and (b) pFB-AAV-
CMV-VEGF-IRES-GFP plasmid with the restriction enzymes. Expected 
bands when digested with MscI: 1033,1288,2471,3503 bp. Expected bands 
when digested with XmaI: 11,1685,1947,4652 bp. DD- double digestion with 
SalI and BamHI, M- molecular marker. Blue arrows indicate expected bands 
and circle indicates the VEGF gene released at ~900 bp. 
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4.2.2. Transfection of recombinant AAV plasmid 
The pAAV-CAG-VEGF-GFP and pAAV-CMV-VEGF-GFP plasmids were 
transfected into the HEK293 and ASC cells to test which promoter had a higher 
transfection efficiency (figure 14). pmaxGFP was used as a positive control. The CAG 
based promoter plasmid showed a higher and more robust gene expression of VEGF-GFP 
in HEK293 cells. pAAV-CAG-GFP plasmid demonstrated a lower transfection compared 
to pAAV-CMV-GFP, as shown in figure 14. Lower transfection efficiency was observed 
in the ASCs, which was expected as these cells have been previously described as being 
difficult to transfect. 
4.2.3. Estimation of VEGF production from the transfected cells 
VEGF secretion into the medium of the transfected cells was estimated by VEGF 
ELISA. pAAV-CAG-VEGF-GFP transfected cell medium showed higher VEGF 
secretion than pAAV-CMV-VEGF-GFP transfected cells, correlating with the 
transfection results (shown in figure 15). Only background level of VEGF secretion was 
obtained from the pAAV-CAG-GFP and pAAV-CMV-GFP transfected cells. 
4.2.4. Production of the recombinant AAV vector 
 Based on the results of transfection and VEGF ELISA, purified pAAV-CAG-
VEGF-GFP plasmid was used for production of recombinant AAV5-CAG-VEGF-GFP 
virus (with a titer of 9.11x1012 vg/ml (1st lot); 6.63x1012 vg/ml (2nd lot)) by the Viral 
Vector Core, at the University of Iowa, using the Baculovirus system. The purity of the 
viral vector was determined by SDS-PAGE and silver staining (figure 16). AAV5-CMV-
GFP (titer 2.5x1014 vg/ml) virus was used as a control virus.  
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Figure 14: Transfection efficiency of VEGF cloned AAV plasmid 
in HEK293 cells 
Transfection of the HEK293 cells with (a) pmaxGFP, (b) pAAV-CMV-GFP, 
(c) pAAV-CMV-VEGF-GFP, (d) pAAV-CAG-GFP, (e) pAAV-CAG-VEGF-
GFP plasmid. Green cells (in the upper panel) are positive for green 
fluorescent protein, indicating successful transfection. Lower panel 
represents respective cells in the bright field. Images taken at 10X 
magnification using a Nikon Eclipse TE-2000-S fluorescence microscope. 
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Figure 15: Estimation of VEGF secretion by pAAV-CAG-VEGF 
and pAAV-CMV-VEGF transfected HEK293 cells. 
(a) Standard graph for VEGF ELISA.  (b) Estimation of VEGF concentration 
secreted in the medium by the HEK293 cells transfected with pAAV-CMV-
GFP, pAAV-CMV-VEGF-GFP, pAAV-CAG-GFP and pAAV-CAG-VEGF-
GFP. Orange bar represents results from a 1:500 dilution and blue bar 
represents 1:100 dilution of medium. 
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4.2.5. Transgene expression of AAV5-CAG-VEGF-GFP in ASCs 
 ASCs transduced with AAV5-CAG-VEGF-GFP at an MOI of 106 vg/cell 
expressed green fluorescent cells positive for VEGF.  A transduction efficiency of around 
5-10% was obtained in the presence of 0.5 µM Hoechst 33342 owing to the low titer of 
AAV5-CAG-VEGF-GFP virus. AAV5-CMV-GFP showed a similar number of green 
fluorescent cells positive for GFP (figure 17). ASCs required a minimum of two or three 
days for transgene expression.   
4.2.6. Transduction of ASCs with AdV5-CMV-VEGF 
 ASCs were transduced with AdV5-CMV-VEGF and AdV5-CMV-GFP (control 
virus) at an MOI of 100. Almost 70-80% of the AdV5-GFP transduced cells expressed 
green fluorescent protein. Since AdV5-VEGF did not have GFP transgene in its 
backbone, we could not estimate the transduction efficiency of AdV5-CMV-VEGF by 
fluorescence microscopy. The VEGF secretion by the Ad-VEGF transduced cells was 
estimated by VEGF ELISA. 
4.2.7. Estimation of VEGF production in the AAV5-CAG-VEGF-GFP and Ad-
VEGF transduced cells 
 VEGF secreted by the transduced cells was estimated by VEGF ELISA (figure 
21). For this experiment, we included another control, an adenovirus encoding the VEGF 
gene (AdV5-VEGF). It is known that adenovirus is able to efficiently transduce ASCs. 
As expected, AdV5-VEGF showed a very high secretion of VEGF when compared to 
AAV5-CAG-VEGF-GFP owing to the higher transduction efficiency. Low background 
levels of VEGF secretion was detected from the control cells and the ASCs medium 
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Figure 16: SDS-PAGE and silver staining on purified viral protein 
The viral protein concentration as estimated by silver staining. The blue 
arrows indicate the AAV viral capsid proteins VP1, VP2, and VP3 are present 
in the expected ratio of ~1:2:10.  
1- Protein Ladder, 2- AAV2/2CMVeGFP, 3- AAV2/2CMVeGFP, 4- 
AAV2/2CMVeGFP, 5- AAV2/2CMVCre, 6- AAV2/2CMVCre, 7- 
AAV2/5CAGVEGFwtIRESeGFP, 8- AAV2/5CAGwtIRESeGFP, 9- 
AAV2/5CAGwtIRESeGFP, 10- AAV2/5CMVCre, 11- AAV2/2CMVempty, 
12- AAV2/2CMVempty. 
 
56 
 
 
Figure 17: Viral transduction in ASCs 
ASCs transduced with recombinant (a) AAV5-CAG-VEGF-GFP (top) and (b) 
control AAV5-CMV-GFP (bottom). Green fluorescent cells are expected to 
be positive for VEGF gene. Blue cells represent nuclei stained with Hoechst 
33342. Images taken at 10X magnification using Nikon Eclipse TE-2000-S 
fluorescence microscope. 
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4.2.8. Characterization of transduced ASCs 
ASC-AAV5-CAG-VEGF-GFP transduced and non-transduced ASCs, were 
characterized by flow cytometry with the selective markers according to the Gold 
Standard IFATS criteria. Higher than 95% of the AAV5-CAG-VEGF-GFP transduced 
ASC strongly expressed the ASCs stem cell markers CD13, CD44, CD73, CD90, CD105, 
while these cells were negative for CD31, CD45 and CD106 (endothelial cell marker, 
hematopoietic cell marker and vascular cell marker respectively) (figures 18 and 19), 
thereby indicating the transduced ASCs maintained their stem markers even after AAV5-
CAG-VEGF-GFP transduction.  
4.2.9. Wound healing ability of the ASCs 
 Monolayers of ASCs were transduced with AAV5-CAG-VEGF-GFP (n=3) ASC-
AAV5-CMV-GFP (n=3), or mock transduced (n=3). Three days later cells were close to 
100% confluent and wounds were made by a pipette tip scratch (on day 0) and were 
analyzed over a period of three days for wound closure (figure 20). By day 1, the wounds 
in the mock transduced cells had started to close, but these cells required nearly 3 days 
for complete healing. Similar to the mock transduced cells, the ASC-AAV5-CMV-GFP 
transduced cells took almost 3 days to heal.  Whereas for the ASC-AAV5-CAG-VEGF-
GFP transduced cells, by day 1, the wound had experienced 70-75% healing. By day 2, 
the wound had completely healed, thus indicating that ASCs expressing VEGF are much 
more potent in healing chronic wounds. 
4.2.10. Allogenic ASCs eluting AAV-VEGF potentiate healing in 2 mm 
organotypic wound model 
 To study the healing efficiency of heterologous ASCs in inducing wound healing, 
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Figure 18: Flow cytometry analysis of AAV-CAG-VEGF-GFP 
transduced ASCs. 
Flow cytometry analysis of stem cell markers show that AAV-CAG-VEGF-
GFP transduced ASCs retain their stemness. (a) Representative gating of the 
stem cell population, (b) unstained ASCs (control), (c) CD106 is a negative 
stem cell marker and is not expressed. More than 98% of the ASCs express 
positive markers (d) CD44, (e) CD73 and (f) CD90. Data collected in 
collaboration with Sunishka Wimalawansa, Greg Gould and Priyanka Sharma. 
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Figure 19: Stem cell marker profile of ASCs transduced with 
AAV-CAG-VEGF-GFP. 
ASC-AAV-CAG-VEGF-VEGF (n=1) shows no expression of markers 
expected to be negative for stem cells (CD106) and >95% of the cells express 
markers expected to be positive for stem cells (CD13, CD44, CD73, CD90 
and CD106). 
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Figure 20: Wound healing assay on ASCs 
Scratch assay on monolayer of non-transduced ASCs (n=3) (top panel), 
AAV5-CMV-GFP transduced ASCs (n=3) (middle panel) and AAV5-CAG-
VEGF-GFP transduced ASCs (n=3) (bottom panel) on (a) day 0, (b) day 1, (c) 
day 2, (d) day 3 showing accelerated healing of ASC-AAV5-CAG-VEGF-
GFP compared to non-transduced ASCs and ASC-AAV5-CMV-GFP. Images 
taken at 4X magnification using Nikon Eclipse TE-2000-S microscope. 
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ASCs were collected and infected with AAV in a small volume and in the presence of 
Hoechst 33342 in order to facilitate transduction. ASC-AAV5-CAG-VEGF-GFP, ASC-
AAV5-CMV-GFP and non-transduced ASC were added as a cell suspension (at a cell 
concentration of 104 cells per wound every 7 days) into the wound punch of the 
organotypic wound model and were assessed over a month long period to compare rates 
of wound healing. Wounds treated with only ASC medium (n=3) were used as controls. 
Wounds treated with ASC-AAV5-CAG-VEGF-GFP (n= 3) healed to almost 45.18 ± 3.8 
% (figure 21) over 32 days whereas the wounds treated with ASC-AAV5-GFP (n=3) and 
non-transduced ASCs (n=3) healed to only about 19.96 ± 2.4 % and 17.78 ± 2.3 % 
respectively over the same time frame. The control wounds only healed 6.19 ± 1.0 %. 
This indicated that ASCs expressing VEGF are more efficient at accelerating the healing 
of chronic wounds when compared to ASCs expressing a GFP and non-transduced ASCs. 
H&E staining performed on the wounds on day 2 and day 32 (figure 22), shows that 
compared to day 2, a significant reduction (*p < 0.001) in the wounded area occurred 
after ASC-AAV5-CAG-VEGF-GFP, ASC-AAV5-CMV-GFP or non-transduced ASCs 
treatment, in comparison to medium only wounds. However no significant difference in 
healing was observed between ASC-AAV5-CAG-GFP or non-transduced ASCs treated 
wounds. Ki67 staining performed on the wounds on day 2 and day 32 (figures 23 and 24) 
shows that the wounds were viable at the termination of the experiment on day 32. 
Wounds on day 2 and day 32 were stained with CD31 antibody to detect blood vessels 
(figure 25 and figure 26). 
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Figure 21: Effect of allogenic ASCs secreting AAV5-CAG-VEGF-
GFP on 2mm wound models. 
ASC-AAV-CAG-VEGF-GFP treated wounds (n=3) significantly enhanced 
wound healing compared to wounds treated with ASC-AAV5-CMV-GFP 
(n=3), non-transduced ASC (n=3) or ASC medium (n=3) from day 8 to day 
32 (*p < 0.001). Healing by non-transduced ASCs was similar to ASC-
AAV5-CMV-GFP (p > 0.05). Blue arrows indicate ASCs addition (104 ASCs 
per wound added every 7 days on Day 0, 7, 14, 21 and 28. Error bars 
represent SD. Analysis performed using two way ANOVA followed by 
Bonferroni test to obtain the p value. 
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Figure 22: Histo-analysis of allogenic wounds treated with ASC-
AAV5-CAG-VEGF-GFP, ASC-AAV5-CMV-GFP, non-transduced 
ASCs or ASC medium on day 2 and day 32. 
Histological observation of allogenic wounds treated with (a) ASC-AAV5-
CAG-VEGF-GFP, (b) ASC-AAV5-CMV-GFP, (c) non-transduced ASCs and 
(d) ASC medium on day 2 (top panel) and day 4 (bottom panel). A significant 
reduction in the wounded area was observed after ASC-AAV5-CAG-VEGF-
GFP, ASC-AAV5-CMV-GFP, non-transduced ASCs treated wounds. Images 
taken at 4X magnification.  
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Figure 23: Ki-67 staining on 2 mm allogenic wounds on 
day 2 showing that the wounds are viable.  
Ki67 staining (in green) on (a) ASC-AAV5-CAG-VEGF treated 
wounds, (b) ASC-AAV5-CMV-GFP treated wounds, (c) non-
transduced ASCs treated wounds, (d) ASC medium treated wounds.  
DAPI staining in blue.  Images taken at 4X magnification using 
Nikon Eclipse TE-2000-S fluorescence microscope. 
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Figure 24: Ki-67 staining on 2 mm allogenic wounds on day 
32 shows that the wounds are viable. 
Ki-67 staining (in green) on (a) ASC-AAV5-CAG-VEGF treated 
wounds, (b) ASC-AAV5-CMV-GFP treated wounds, (c) non-transduced 
ASCs treated wounds, (d) ASC medium treated wounds.  Images taken 
at 4X magnification using Nikon Eclipse TE-2000-S fluorescence 
microscope. 
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Figure 25: CD31 staining on 2 mm allogenic wounds on day 2 
marking the endothelial cells. 
CD31 staining (in red ) on (a) ASC-AAV5-CAG-VEGF treated wounds, (b) 
ASC-AAV5-CMV-GFP treated wounds, (c) non-transduced ASCs treated 
wounds, (d) ASC-medium treated wounds. Images taken at 4X magnification 
using Nikon Eclipse TE-2000-S fluorescence microscope. 
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Figure 26: CD31 staining on 2 mm allogenic wounds on day 32 
marking the endothelial cells. 
CD31 staining (in red) on (a) ASC-AAV5-CAG-VEGF treated wounds, (b) 
ASC-AAV5-CMV-GFP treated wounds, (c) non-transduced ASCs treated 
wounds, (d) ASC medium treated wounds.  Images taken at 4X magnification 
using Nikon Eclipse TE-2000-S fluorescence microscope. 
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Few endothelial cells or blood vessels were observed in the ASC-AAV5-CAG-VEGF-
GFP treated wound on day 32 (shown in figure 26a). No obvious difference was observed 
in the formation of the blood vessels after treating the wound with ASC-AAV5-CAG-
VEGF-GFP. 
4.2.11. Autologous ASCs secreting AAV-VEGF enhance wound healing in 2 
mm wound models 
 To determine the effect of autologous ASCs in potentiating wound healing, the 2 
mm wound models were treated with ASC-AAV5-CAG-VEGF-GFP (n=4), ASC-AAV5-
CMV GFP (n=4) (at a cell concentration of 104 cells/wound/7 days), or ASC medium 
(n=4) for a month. Though complete closure was not observed, the wound models treated 
with autologous ASC-AAV5-CAG-VEGF-GFP showed a closure of 49.18 ± 4.7 % (as 
shown in figure 27). The wound models treated with ASC-AAV5-CMV-GFP closed to 
about 31.38 ± 6.2 % whereas the control wounds treated with ASC medium showed only 
7.65 ± 2.2 % closure. H&E staining of the sections taken at day 28 shows that ASC-
AAV5-CAG-VEGF-GFP treated wound had a scarred healing with a lot of eosin-reactive 
(blue) deposition in the wounded area (figure 28). 
4.2.12. Autologous ASC secreting AAV-VEGF enhance wound healing in 3 
mm wound models 
 To determine the effects of ASCs secreting VEGF in healing 3mm wound 
models, the wound models were treated with ASC-AAV5-CAG-VEGF-GFP (n=2), ASC-
AAV5-CMV-GFP (n=2), non-transduced ASCs (n=2), or ASC medium (n=2) for a 
period of one month. Since these were 3 mm wound models, 105 autologous ASCs per 
wound per 7 days were used for the treatment. It was observed that the wounds treated
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Figure 27: Effect of autologous ASCs (104 ASCs per wound) 
secreting VEGF on 2mm wound models. 
Enhanced wound closure observed in ASC-AAV-CAG-VEGF-GFP treated 
wounds (n=4) compared to wounds treated with ASC medium (n=4) and 
ASC-AAV5-CMV-GFP (n=4) (p < 0.001).ASC-AAV5-CMV-GFP can 
induce healing relative to ASC medium treated wounds but not as 
effectively as ASC-AAV-CAG-VEGF-GFP treated wounds. Arrows indicate 
ASCs addition to the wounds on day 0, 7, 14, 21. Error bars represent SD. 
Analysis performed using two way ANOVA followed by a Bonferroni test 
to obtain the p value. 
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Figure 28: Histo-architecture of autologous ASC treated wounds 
on day 32. 
H&E staining of autologous wounds treated with (a) ASC-AAV5-CAG-
VEGF-GFP, (b) ASC-AAV5-CMV-GFP and (c) ASC medium on day 28. 
Wounds treated with ASC-AAV5-CAG-VEGF-GFP show partial healing with 
a lot of cellular deposition in the wounded area. Images taken at 4X 
magnification. 
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with ASCs eluting VEGF showed around 25.07 ± 1.1 % closure (as shown in figure 29) 
whereas the wounds treated with ASC-AAV5-CMV-GFP  or non-transduced ASCs 
(ASCs NoT)  showed about 18.01 ± 0.6 % and 16.73 ± 0.3 % healing respectively. The 
control wounds treated with ASC medium healed only by 8.12 ± 1.0 %.  
4.2.13. Autologous ASCs secreting AdV-VEGF enhance wound 
healing in 3 mm wound models 
 Adenovirus can transduce ASCs at a higher level than adeno-associated virus and 
AdV-VEGF transduction yields high levels of VEGF secretion. To determine whether 
Ad-VEGF can induce more healing when compared to AAV5-CAG-VEGF-GFP (figures 
21, 27 and 29), wound models were treated with ASC-Ad-CMV-VEGF (n=8), ASC-Ad-
CMV-GFP (n=8), non-transduced ASCs (n=8) and ASC medium (control) (n=8) (figure 
30). Since the VEGF secretion was much higher in the Ad-CMV-VEGF transduced 
ASCs when compared to AAV5-CAG-VEGF-VEGF transduced ASC, 104 ASC were 
added per wound every 7 days for the treatment of the wounds. We observed that the 
wounds treated with ASC-Ad-CMV-VEGF healed to around 29.00 ± 1.9 % whereas the 
ASC-Ad-CMV-GFP and non-transduced ASC (ASCs NoT) treated wounds healed to 
22.77 ± 1.4% and 20.34 ± 1.0 % respectively. The control wounds treated with only ASC 
medium healed around 8.21 ± 1.2 %. ASC-AAV5-CAG-VEGF-GFP treated wound 
showed significant healing (*p < 0.001) compared to other groups. ASC-AAV5-CMV-
GFP or non-transduced ASCs treated wound showed no significant difference in healing.  
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Figure 29: Effect of autologous ASCs (105 ASCs per wound) 
transduced with AAV5-CAG-VEGF-GFP on 3 mm wound 
models. 
ASC-AAV-CAG-VEGF-GFP (n=2) significantly enhanced wound 
healing compared to wounds treated with ASC-AAV-CMV-GFP (n=2), 
non-transduced ASC (ASC NoT) (n=2) or ASC medium (n=2) starting 
from day 5 until day 25(p < 0.001). ASC NoT and ASC-AAV5-CMV-
GFP have similar healing efficiency (p > 0.05); however both show 
significantly three times higher healing than ASC medium treated 
wounds (p < 0.001). Arrows indicate ASCs addition to the wounds on 
day 0, 7, 14, 21. Error bars represent SD.  Analysis performed using two 
way ANOVA followed by Bonferroni test to obtain the p value. 
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Figure 30: Effect of autologous ASCs (104 ASCs per wound) 
transduced with AdV-VEGF on 3 mm wound models. 
ASC-AdV-CAG-VEGF-GFP (n=8) enhanced wound healing compared to 
wounds treated with ASC-Adv-CMV-GFP (n=8), ASC NoT (n=8) or ASC 
medium (n=8) from day 10 to day 26 (p < 0.001).Wounds treated with non-
transduced ASCs and ASC-Ad-CMV-GFP showed the same healing efficacy 
(p > 0.05). Arrows indicate ASCs addition to the wounds on day 0, 7, 14, 21. 
Error bars represent SD. Analysis performed using two way ANOVA 
followed by Bonferroni test to obtain the p value. 
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4.3. Discussion 
 Adipose derived stem cells hold great promise as a therapy for chronic wound 
healing through stimulation of re-epithelialization, keratinocyte migration, capillary 
formation, tissue granulation, and angiogenesis (Kwon et al., 2015). ASCs have the 
ability to differentiate into adipocytes, chondrocytes or osteocytes upon induction with 
respective differentiation medium (Kim et al., 2007).  ASCs also have the potential to 
secrete EGF, FGF, VEGF, PDGF, HGF, TGF-β (Park et al., 2015). ASCs by themselves 
are not enough to induce complete wound closure, additional growth factors or cytokines 
are required for inducing wound closure (Kwon et al., 2015).  
 Among the growth factors, vascular endothelial growth factor (VEGF) plays a 
pivotal role in wound healing by promoting angiogenesis. VEGF permeates the blood 
capillaries and increases the blood flow into the wounded area thereby increasing the 
oxygen and nutrient flow into the wounds, thus accelerating wound healing (Nauta et al., 
2012). Thus, ASCs expressing VEGF may an important tool for potentiating wound 
healing. Viral vector mediated gene therapy via adenovirus, adeno-associated virus or 
retrovirus is one of the most effective ways for expressing VEGF in ASCs. Both 
retrovirus or adenovirus transduction can result in a high amount of VEGF secretion. 
However adenovirus mediated gene therapy can cause a robust inflammatory response 
(Ritter et al., 2002). In the case of retrovirus, because of its integration into the 
chromosomes can cause insertional mutagenesis (Yi et al., 2011). Although AAV has 
low cell transducing ability, it is one of the most effective vectors for gene expression 
because of its lack of pathogenicity and non-toxic nature (Deodato et al., 2002). 
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 In our study, we isolated ASCs from patients by liposuction or after 
abdominoplasty and expanded them in culture in DMEM F12 medium along with FBS 
and antibiotic and antimycotic to provide nutrients for survivability and growth of ASCs, 
and protection from bacterial or fungal contamination, respectively. We characterized the 
ASCs by flow cytometry with positive stem cell markers (CD13, CD44, CD73, CD90, 
and CD105) and negative stem cell markers (CD31, CD45 and CD106). The positive 
markers were expressed in more than 95% of the cells and the negative markers were 
expressed at less than 1% (data not shown) thus indicating that the ASCs cells derived 
from patients were indeed stem cells. ASCs were cultured up to 3rd passage before being 
used for cell therapy. ASCs also differentiate into adipocytes, chondrocytes, and 
osteocytes (data not shown) upon induction with the respective medium. ASCs 
maintained their stem cell nature up to the sixth passage after which they started to lose 
their stem nature and stopped dividing (McIntosh et al., 2006).  
 To make the AAV vector expressing VEGF, I first cloned the VEGF gene into 
two AAV plasmid vector pAAV-CMV-GFP and pAAV-CAG-GFP. It was observed that 
the CAG-based AAV plasmid had more VEGF transfection than the CMV-based plasmid 
as evidenced by higher VEGF secretion in the medium as estimated by VEGF ELISA. 
Transfection and VEGF secretion was less in pAAV-CMV-VEGF-GFP than pAAV-
CAG-VEGF-GFP probably because VEGF cloning was not entirely successful into the 
pAAV-CMV-GFP plasmid as its cloning site might have been disrupted as evidenced by 
the missing bands seen in pAAV-CMV-VEGF-GFP in figure 13. Based on the higher 
VEGF secretion in pAAV-CAG-VEGF-GFP, we chose this plasmid for AAV vector 
production from University of Iowa Viral Vector core.   
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To make ASCs express more VEGF, ASCs were transduced with AAV-CAG-
VEGF-GFP, however only around 10-15% of the ASCs were transduced. Flow cytometry 
analysis of the AAV-CAG-VEGF transduced cells also confirmed the stemness of the 
transduced ASCs as evidenced by the expression of the positive markers in more than 
95% of the cells and negative markers in less than 1%. When the ASCs were transduced 
with AdV-CMV-VEGF more than 80% of the ASCs were transduced and very high 
VEGF secretion was obtained when compared to the AAV-CAG-VEGF transduced cells. 
However excessive VEGF secretion can lead to tumor formation thus being cancerous for 
tissue (Herve et al., 2008). 
I studied wound healing ability in ASCs in vitro by performing a scratch assay on 
non-transduced ASCs and ASCs transduced with AAV-CAG-VEGF or AAV-CMV-GFP. 
ASCs transduced with AAV-CAG-VEGF healed the scratch wound completely within 2 
days whereas the AAV-CMV-GFP transduced ASCs and non-transduced ASCs took 
three days to heal, thereby suggesting VEGF supplementation with ASCs can potentially 
accelerate healing. 
Wound healing ability was then studied in 2 mm autologous or allogenic 
organotypic wound models. Wounds treated with 104 ASC-AAV-CAG-VEGF healed 
nearly 50%, athough they could not completely induce wound closure, whereas the 
wounds treated with 104 ASC-AAV-CMV-GFP or 104 non-transduced ASCs showed 
around 25-30% healing. The control wounds treated with ASC medium could only heal 
to 6-7% suggesting ASC medium by itself was ineffective in promoting wound healing. 
Both autologous and allogenic ASCs were effective in potentiating healing. 
Histochemical analysis of the allogenic wounds showed reduction in the wounded area 
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(on day 32) of the ASC-AAV-CAG-VEGF, ASC-AAV-CMV-GFP and non-transduced 
ASCs treated wounds but the control wounds showed almost no reduction compared to 
day 2. Immunostaining with Ki-67 showed Ki-67 positive staining (on day 32) in all the 
wounds suggesting the wounds were viable at the termination of the experiment. CD31 
immunostaining showed few blood vessels in the dermis of the wound. We expected to 
see more blood vessels in the ASC-AAV-CAG-VEGF treated wounds, however, we 
could see only a very few which was not obviously different from day 2.  When stained 
with cytokeratin 5 or cytokeratin 14, cytokeratin positive cells were observed in the 
epidermis of the healing wounds. No significant difference in the healing rate of the 
autologous versus allogenic ASCs was observed most probably because the wound 
models lack an immune system thereby reducing the chances of rejection of allogenic 
ASCs.   
We also studied wound healing ability in 3mm allogenic wounds. Since the 
wound size was larger, we used ASC-AAV-CAG-VEGF, ASC-AAV-CMV-GFP, or non-
transduced ASCs for treating wounds at a cell count of 105 per wound. Wounds treated 
with ASCs expressing VEGF showed around 25-30% healing whereas wounds treated 
with non-transduced ASCs or ASC-AAV-CMV-GFP showed around 15-20% healing 
while the control wounds healed to about 8-9%. This suggests that ASCs alone may have 
a more difficult time healing larger wounds because of the larger surface area of the 
wounds and probably due to inefficient migration or proliferation of the few ASCs in the 
wounded area. 
We also used adenovirus-mediated VEGF transduced ASCs to study healing in 
3mm wound models. AdV transduced ASCs at a count of 104 ASCs were used to treat the 
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wound models. We expected that due to more VEGF secretion in the Ad-CMV-VEGF 
transduced ASCs, accelerated healing and complete closure will be observed in the 
wounds treated with ASC-Ad-CMV-VEGF. However only 30% closure was obtained, 
suggesting that AdV-transduced ASCs secreting VEGF was not likely any better than 
AAV-VEGF in mediating healing. This could also be possibly because 104 ASCs per 
wound is not enough for inducing complete closure or because very high amount of 
VEGF secretion can limit healing by becoming cancerous to the tissue (Herve et al., 
2008). 
Though we could not obtain complete closure, we could show that VEGF 
supplementation along with ASCs can potentially accelerate wound healing. We expect 
that with supplementation of additional growth factors (EGF, FGF, TGF, PDGF or a 
combination of growth factors) or treatment for a longer time will induce complete 
wound closure.  
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Chapter 5: Red light exposure 
5.1. Rationale 
Adipose derived stem cells, when harvested from patient’s fat, were passaged 
sequentially three times for facilitating ASCs selection from stromal vascular fraction 
before being used for transplantation purposes. They are the most viable between third 
and the fifth passage after which they start losing their viability, shape, structure, and 
stem markers (McIntosh et al., 2006). And by passage eight, they completely lose their 
stemness. Thus, the optimum use of ASCs should be within the time when they are in 
between the third and the fifth passage. This acts as a limiting factor for cell therapy 
because ASCs might not have reached sufficient numbers or need to be manipulated 
beyond their fifth passage for the patient specific needs. Red light therapy (660 nm) has 
been shown to stimulate proliferation of stem cells (Choi et al., 2013). Also, red light 
therapy can accelerate healing of tissues by enhancing viability of ASCs and potentiating 
angiogenesis in an ischemic mouse model (Park et al., 2015). Based on this I 
hypothesized that exposure of ASCs to red light will increase their proliferation and also 
aid in maintaining stemness beyond the 7th passage. Calu3 cells, a transformed lung 
cancer cell line, were used as a control cell line and also allowed me to study the effect of 
red light on cancerous cell proliferation. 
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5.2. Results  
5.2.1. Red light exposure increases Calu3 cell count 
 Calu3 cells were seeded at a count of 7.5 x 104 cells per well in a 12-well plate 
and two days later were exposed to red, green, or ambient light for 15 minutes (figure 
31). Two days after exposure, a one and a half fold increase (p < 0.001) in the count of 
red light exposed cells was observed compared to the green or ambient light exposed 
cells. The number of the green light exposed cells was similar to that of the ambient light 
exposed cells. When the cell counts of the red, green or ambient light exposed cells were 
compared to the seeding count, nearly five-fold increase was seen in the red light exposed 
cells (p < 0.001) whereas the green light or the ambient light exposed cells showed a 
three-fold increase (p < 0.001), thereby suggesting that the red light exposure 
significantly enhanced the cell proliferation of the Calu3 cells.  
5.2.2. Red light exposure in ASCs increases cell count 
 ASCs seeded at 4 x 104 cells per well were exposed to red (n=3), green (n=3), or 
ambient light (n=3) for 15 minutes two days after seeding (Day 0) (figure 32). After two 
days (Day 4), red light exposed cells showed a 1.2 times higher cell count (p < 0.01) 
when compared to the ambient light exposed cells or green light exposed cells.  When the 
cell count of these red, green, or ambient light exposed cells were compared to that of the 
number of cells seeded, the red light exposed cells increases by almost one and a three 
fourth times of the seeding count (p < 0.001) and the ambient light or green exposed cells 
increased by one and a half times (p < 0.001).  
81 
 
 
Figure 31: Effect of red light exposure on Calu3 cell growth 
Exposure of Calu3 cells to red light increases the cell count by 1.5 times 
relative to green light or ambient light exposure (p < 0.001). Error bars 
represent SD for n=3 experiments. Analysis performed using two way 
ANOVA followed by Bonferroni test to obtain the p value. 
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Figure 32: Effect of red light on ASCs cell count 
Exposure of ASCs to red light 2 days after seeding increases the cell count by 
1.2 times relative to green light or ambient light exposure, as counted on day 
4 (p < 0.01). Error bars represent SD for n = 3 replicates. The experiment was 
repeated 3 times and data shown are from one representative experiment. 
Analysis performed using two way ANOVA followed by Bonferroni test to 
obtain the p value.                                                                                        
 
83 
 
5.2.3. Red light exposed cells maintain their stemness at passage 8 
 ASCs not exposed to red light stopped growing at passage 7 (data not shown). By 
contrast, ASCs exposed to red light continued to grow and retain a stem-like morphology. 
To determine whether the red light exposed ASCs at passage 8 retained their stem 
markers, red light exposed cells (n=1) were characterized by flow cytometry with the 
stem markers according to IFATS standard. The ASCs showed that the positive markers 
CD13, CD44, CD73, CD90 and CD105 were expressed on more than 95% of the cells 
whereas the negative markers showed that less than 1% of the cells expressed the 
negative markers (CD31, CD45, CD106; figures 33 and 34), which indicated that the 
ASCs maintained their stem markers even after exposure to red light.  
5.2.4. Red light exposure potentiates wound healing 
 Given the benefit of increased cell growth, I hypothesized that exposure of 
organotypic wound models would lead to wound closure. 1.5 mm2 wound models were 
exposed to red light (670 nm) (n=3) or ambient light (n=3) every other day for 20 days. 
Exposure to red light from the bottom or the dermal side of the wound model caused 
59.15 ± 0.3% decrease in the wound area whereas the ambient light exposed wounds only 
showed 4.20 ± 1.3% closure (as shown in figure 35). Given the plateau of closure by day 
10, it is likely that there is a maximum amount of closure that red light can do on its own. 
5.3. Discussion 
Red light therapy is a successful therapeutic tool in regenerative medicine (Amid 
et al., 2013). Exposure to red light leads to increased collagen synthesis, cytokine and 
growth factor secretion, increased angiogenesis, and reduced pain and inflammation 
(Park et al., 2015). 
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Figure 33: Flow cytometry analysis of stem cell markers show 
that red light exposed ASCs at passage 8 retains their stemness. 
 (a) Representative gating of the stem cell population, (b) unstained ASCs 
(control), (c) CD31 is a negative stem cell marker and is not expressed. More 
than 98% of the ASCs express positive markers (d) CD13, (e) CD73 and (f) 
CD105. N = 1 donor. 
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Figure 34: Stem cell marker profile of red light exposed passage 
8 ASCs. 
Expression of markers expected to be negative for stem cells (CD31, CD45, 
CD106) was less than 0.5% whereas more than 95% of the red light exposed 
cells (n=1) express markers expected to be positive for stem cells (CD13, 
CD44, CD73, CD90 and CD106). N = 1 donor. 
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Figure 35: Red light exposure induces wound closure in 
organotypic wound models. 
Time course of percentage of wound closure obtained in red light exposed 
wounds versus ambient light exposed wounds (n=3). Error bars represent SD. 
Red light exposed wounds show a significant difference (p <0.001) in healing 
compared to ambient light treated wounds (control) from day 1 to day 20. 
Analysis performed using two way ANOVA followed by Bonferroni test to 
obtain the p value. 
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In culture, ASCs generally tend to lose their viability and stemness after the 7th 
passage and stem cells from elderly patients do not replicate well, thereby limiting its 
application in the transplantation setting (McIntosh et al., 2006). When ASCs beyond 
passage 7 were exposed to red light, an increase in viability and cell number is observed. 
The increase in viability can likely be attributed to a decrease in senescence or apoptosis 
of red light exposed cells (Park et al., 2015). Also, exposure to red light leads to an 
increase in proliferation of ASCs compared to ambient light exposed cells. Interestingly, 
the red light exposed cells maintained their stem markers (with the expression of the 
positive stem cell markers by more than 96% of the cells and the negative markers 
expressed at less than 1%).  This suggests that red light exposed ASCs can be used for 
transplantation even after the 7th passage, giving hope that stem cells from elderly 
patients may be responsive to red light and could be expanded for therapy. The cells 
exposed to green light showed a small increase in cell count when compared to the 
ambient light exposed cells but not statistically significant. Future experiments will test 
whether a combination of red light and green light may be able induce a further increase 
in cell proliferation. Calu3 cells proliferate at a much higher rate than the ASCs. This can 
be due to the fact that Calu3 cells are cancerous cells while ASCs belong to the primary 
cells category. Thus, cancerous cells proliferate at a much faster rate than the primary cell 
lines. Red light therapy is known to increase cell proliferation to a much faster rate.  
While this is extremely advantageous for ASCs, it is a possibility that cancerous cells 
would also increase their proliferative potential, posing a huge threat to the patient. 
It is known that the effect of red light exposure is dose dependent, meaning low 
dosages of red light exposure can cause inefficient healing while high doses can have 
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deleterious effects and damage tissue. It can cause re-pigmentation of vitiligo and 
depigmentation of hyper-pigmented lesions depending on the dosimetry parameter (Avci 
et al., 2013). Exposure to red light is known to lead to increased secretion of FGF, 
VEGF, and HGF. Elevated levels of these growth factors stimulate cell migration and 
proliferation, angiogenesis, and inhibit apoptosis (Park et al., 2015). Low level light 
therapy (LLLT, 600-700 nm, like red light therapy but a broader band width) also induces 
osteoblast differentiation, proliferation and maturation (Amid et al., 2013). LLLT can 
induce healing radiation related damages by secretion of minerals (Fernandes et al., 
2013).   
Exposure of the wound models to red light also enhanced closure when compared 
to the ambient light exposed wounds.  Previous studies have shown that red light has 
stimulatory effects on the cells in the damaged area which thereby induce wound healing 
by enhancing cell migration and cell proliferation in the wounds via increased secretion 
of growth factors like EGF, FGF , PDGF  (Park et al., 2015) ( Avci et al., 2013). 
However, in our model, we do not know yet what is stimulating wound closure. With 
Bio-plex assays, cytokines and growth factors contributing to wound closure can be 
determined.  
Complete healing was not observed in the wound models when exposed to red 
light. The inefficiency in healing can be due to suboptimal dose of red light, insufficient 
time, and insufficient cells to divide and fill in the wound, or indicate that a combination 
of the red light and ASCs would be required. It is expected that a combination of red light 
therapy with supplementation of ASCs will lead to enhanced secretion of angiogenic 
growth factors, and increased cell migration and proliferation (Park et al., 2015). LLLT 
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can induce skin rejuvenation by secretion of IL-1β and TNF-α, which thereby recruits 
MMPs and initiates collagen synthesis (Avci et al., 2013). Thus red light therapy is a 
non-invasive, painless procedure which can be applied in dermatology for treatment of 
chronic wounds, lesions, acnes, burns, and scars (Avci et al., 2013). While red light has 
limitations in our wound model, it may be better in vivo due to endogenous pools of stem 
cells.
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Chapter 6: Discussion 
Wound healing is a complex process requiring the regulation of cell migration, 
collagen deposition, and re-epithelialization. Studies have shown that adipose derived 
stem cells (ASCs), because of their ability to differentiate, regenerate, and secrete growth 
factors, can potentiate the process of wound healing (Kim et al., 2007). Among the 
growth factors, VEGF has shown a pivotal role in wound healing by promoting 
angiogenesis. Deodata et al. showed that high amount of VEGF secreted by the 
keratinocytes in the wound bed and in migrating keratinocytes accelerated wound healing 
(Deodata et al. 2002). VEGF promotes rapid wound closure by enhancing blood and 
nutrient flow to the wound site, thereby facilitating healing (Nauta et al., 2012). This 
suggests that expression of VEGF by ASCs is an important tool in wound healing. 
Animal studies and clinical trials have indicated that topical application of VEGF protein 
can lead to degradation of the protein by the time it reaches the wound site thereby 
requiring large doses of VEGF protein (Galeano et al. 2004). Viral vector mediated gene 
therapy using adeno-associated virus is one of the most effective ways for gene 
expression in cells and tissues because of the lack of pathogenicity of AAV and relative 
stability of AAV in vivo and sustained production and secretion of growth factor 
(Gauglitz et al., 2011). 
ASCs have been used in clinical trials to treat calvaria defects using SVF (stromal 
vascular fraction). SVF resulted in new bone formation and complete healing of the 
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calvaria defect (Lendeckel et al., 2004). SVF fraction has also been used in clinical trial 
for treatment of myocardial infarction (Yoshimura et al., 2008). ASCs have been used for 
treating scars and osteogenic defects (Mesimaki et al., 2009), but clinical phase I and II 
trial have not been completed yet. Clinical trials for treatment of perianal fistula, Crohn’s 
disease, GVHD, (Hassan et al., 2014) have also been initiated. ASCs therapy holds much 
promise. 
We were interested in applying ASCs to wound healing. However, in vitro assays 
are limited and it is unclear that studies in animals will truly be relevant to humans. We 
therefore designed and initiated the use of organotypic wound models obtained from 
patient skin by abdominoplasty or brachioplasty to study wound healing. These tissues 
are usually discarded after surgery but are a robust source of ASCs and the skin is usually 
healthy. We tried both 2mm or 3mm punches to create wounds in the 8 mm punch 
models. The 8 mm punch size was chosen because this size fits well in transwells. 
Transwells have semipermeable membranes and provide support the skin structure 
because they can then be maintained at an air liquid interface. The bottom part of the well 
is exposed to ASC medium, which provides nutrients to the wounds, and the top part of 
the transwell is exposed to air. The wound models were viable for at least four months as 
seen by the MTT assay (figure 11). Measurements taken on the wounds over a period of 
time indicated that the wounds only supplemented by ASC medium did not close by itself 
thus indicating that these are chronic wounds. Histoarchitecture of the wound studied by 
H&E staining shows that the structural anatomy of the skin contains all three layers, 
epidermis, dermis and fat. These wound models are advantageous over using mice or rat 
models because mice are anatomically, hormonally, and metabolically different than 
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humans. Also mice live for an average of one or two years, hence replicating the studies 
based on the effects seen in mice are debatable. This multidimensional wound model 
culture system can mimic the chronic wound environment of a human in vivo and 
therefore can be used as a model to study wound healing and help in developing a 
therapeutic approach to accelerate wound healing. 
We isolated ASCs from patients and cultured them in vitro to be used for 
experimentation. Expression of the stem cell markers by the ASCs were characterized by 
flow cytometry according to the IFATS standard. The ASCs remained viable and 
maintained their stem cell qualities between passage three to six, after which they started 
losing their stem-like nature and stopped dividing. In order to preserve them long term, I 
exposed them to red light. I showed that red light exposure increased their viability and 
also helped in maintaining their stem markers, at passage 8 ASCs could then be 
subcultured and as long as they were exposed to red light, maintained their ability to 
divide and their stem-like appearance. While the ambient light-exposed ASCs at passage 
9 had lost their viability and their ability to expand, red light exposed cells could continue 
to 15 or more passages (data not shown). This may be because red light exposure 
decreases the rate of apoptosis and increases rate of proliferation and regeneration (Park 
et al., 2015), thereby increasing viability. Red light exposed cells also have been shown 
to secrete a larger amount of growth factors like VEGF and EGF. Future experiments will 
determine whether the levels of growth factors (like VEGF, FGF, EGF, PDGF, retinoic 
acid) change or there are other metabolic changes upon exposure to red light. 
To make the ASCs express increased levels of VEGF, I transduced the ASCs with 
AAV-VEGF-GFP or Ad-VEGF vector. The ASCs transduced with AAV vector showed 
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only about 10-15% transduction efficiency whereas almost 80% of the ASCs were 
transduced with adenovirus. The ASCs transduced with AAV-VEGF-GFP expressed 
their stem markers after transduction, as shown by the flow cytometry (figure 19) 
indicating that transduction does not alter the ASCs stem cell profile. Though low levels 
of the VEGF secretion in the AAV-transduced ASCs were obtained (figure 17), it can be 
considered an advantage as excessive VEGF secretion can be cancerous to cells and 
damage them (Basu et al., 2009). This indicates that AAV is a suitable vector for 
moderate and sustainable VEGF gene expression.  
We analyzed the healing ability of the AAV-VEGF-GFP transduced ASCs in vivo 
by scratch assay, performed on a monolayer of ASCs. It was seen that in the ASC-AAV-
VEGF-GFP transduced cells, the scratch healed by almost 75-80% by day 1 and had 
healed completely by the second day. However, in the ASC-AAV-GFP transduced and 
non-transduced ASCs the scratch nearly took three days to heal. Whether the healing had 
taken place due to increased cell division, regeneration, or migration of ASCs has not yet 
been studied. Overall, these data indicate that ASCs secreting VEGF can potentiate 
wound healing in vitro as VEGF acts as a cell mitogen.  
In our study, we tested the efficiency of ASC-AAV-VEGF-GFP in accelerating 
wound healing in vivo by comparing it to the healing rate obtained by ASC-AAV-GFP,  
non-transduced ASCs in both autologous and allogenic organotypic wound models. Each 
of the wounds was treated with 104 transduced or non-transduced ASCs. We showed that 
in the 2 mm wound models, ASCs eluting VEGF could close the wound up to around 45-
50% in both allogenic and autologous wounds whereas the non-transduced ASCs or 
ASCs expressing GFP could only induce around 25-30% closure. The control wound 
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models treated with ASC medium healed only by 6-7% in a period of one month. This 
suggested that though ASCs by themselves can induce some closure in the wounds, they 
are not as potent as ASCs secreting VEGF in inducing wound closure. Also, since ASCs 
expressing GFP could heal the wounds to almost the same extent as the non-transduced 
ASCs, we can say that the healing in wounds treated with ASC-GFP is because of the 
ASCs, while GFP does not contribute to wound healing. This indicates that the ASCs 
secreting VEGF can significantly enhance wound closure when compared to non-
transduced ASCs or ASC-AAV-GFP.  H&E staining performed on the wound models on 
day 2 and day 32 showed reduction in the wound area of ASC-AAV-VEGF-GFP treated 
wound, while the wound size in the control group was almost equal to the day 2 time 
point. Immunostaining performed on the wounds with Ki67 showed mitotically active 
cells in the epidermis region indicating that the wounds were still alive at the termination 
of the experiment. However, when the sections of the wounds were stained with CD31 
antibody, we did not see a significantly greater number of blood vessels in the group 
treated with ASC-AAV-VEGF-GFP as was hypothesized. This probably is due to the fact 
that the wound models do not have a network of active blood vessels and blood supply, 
so there was no detectable de novo blood vessel formation in the wounds treated with 
ASC-AAV-VEGF-GFP.  
  We did not see any significant difference in healing when we used autologous 
versus allogenic ASCs in the wounds.  This probably is due to the fact that these wound 
models do not have an active immune system to cause any host versus recipient rejection 
or immune reaction. We also used 3mm wound models to study wound healing. Since the 
wound sizes of the 3mm models were bigger when compared to the 2mm models, we 
95 
 
increased the dosage of ASCs and hence used 105 ASCs per wound. We grouped the 
wound models in four categories, where one group was treated with ASC-AAV-VEGF-
GFP, the second group with ASC-AAV-GFP, the third group with non-transduced ASCs 
and the fourth group as the control group treated with ASC medium. We saw that a 
closure of around 27-30% was observed in the group treated with ASC-AAV-VEGF-GFP 
while the wounds treated with ASC-AAV-GFP or on transduced ASCs healed only to 
around 15-20%. The control wounds treated with ASC medium alone showed very 
minimal healing. This could be because the wounds were bigger in size and would have 
probably required a larger ASCs dosage or a combination of ASCs and cytokine therapy.  
We also used adenovirus transduced ASC-VEGF and ASC-GFP to investigate 
wound healing in 3 mm models. We had expected that with adenovirus transduction, 
leading to more VEGF production by ASCs (figure 34), there would be accelerated 
healing and complete closure of the wounds treated with ASC-Ad-VEGF. However, there 
was only about 30% closure in the 3 mm models, similar to what we had seen in the 
wounds treated with AAV transduced ASC-VEGF, which indicated that ASC-Ad-VEGF 
was as effective as ASC-AAV-VEGF in potentiating healing (figure 21, 27, 29). 
Potentially there is a threshold amount of VEGF that improves closure and levels beyond 
that does not help healing. It is also possible more time for closure would have made a 
difference, however the plateau of healing argues against this. 
Red light exposure is known to increase growth factor expression, such as VEGF 
(Park et al., 2015). We studied the effect of red light on wound healing by exposing 
wounds to red light and analyzing its efficacy in inducing closure compared to ambient 
light exposed cells. We observed closure of about 50% in red light exposed wounds in 
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three weeks after which the healing rate became stagnant (figure 35). However, this was 
in smaller wounds. Despite this, it is expected that wounds and ASCs exposed to red light 
led to increased secretion of growth factors, more cell migration, and proliferation (Park 
et al., 2015).  This indicates that red light exposure can potentially accelerate wound 
healing and complete wound closure can be achieved if a combination of red light 
therapy, cell therapy, and gene therapy is implemented. 
Attaining complete wound closure in patients is particularly important because 
ineffective or partial healing can worsen the condition of the patients physically and 
mentally. Partially healed wounds can also be a site for infection.  To attain complete 
wound closure, studying the conditions of chronic wounds and the factors affecting their 
healing have to be analyzed properly. Complete wound closure was obtained in the 
mouse models when treated with ASCs secreting VEGF using biodegradable PBAE (poly 
β-amino ester) nanopolymer within 14 days (Nauta et al., 2012). This is because mice 
have an active blood vessel and blood supply. Supplementation of VEGF can therefore 
increase the blood vessel formation and also increase blood flow into the wounds, thereby 
providing oxygen and nutrients to wounds and facilitate wound closure. In our study, 
complete closure was not obtained in any of the wound models treated with ASC-AAV-
VEGF or ASC-Ad-VEGF at a concentration of 104 ASCs per wound or 105 ASCs per 
wound. This indicated that ASCs therapy with only VEGF gene transfer potentially 
cannot induce complete wound closure and the healing conditions have to be more 
personalized.  However in viable wound bed with a blood network system, VEGF may 
stimulate growth of blood vessels and cause increase in blood flow, and thereby 
potentiate wound healing process. Accelerated wound healing and a substitution of a 
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cocktail of growth factors to induce complete wound closure are required. Future studies 
will perform a Bio-plex on the medium and cells obtained from the chronic wounds, in 
comparison to ASC-AAV-VEGF-GFP and red light exposed, to identify the 
biomolecules (extra cellular matrix (ECM), collagen, keratinocytes, and fibroblasts), 
cytokines, growth factors, and pathways that can contribute to wound healing. Human 
wound healing PCR arrays can be performed to analyze the different cytokines, 
remodeling enzymes, extracellular matrix proteins, growth factors (like FGF, HBEGF 
(Heparin binding EGF like growth factor) , HGF (hepatocyte growth factor) , IGF 
(insulin growth factor), MIF (macrophage migration inhibitory factor) , PDGF, TGF 
(transforming growth factor), TNF (tumor necrosis factor), CSF (colony stimulating 
factor), ANGPT (angiopoietin), VEGF ) expressed in the injured tissues and healing 
wounds. Substituting the chronic wounds accordingly with the combination of 
biomolecules, growth factors and cells may be the solution that mediates complete wound 
closure.   
Contrasting to our hypothesis, VEGF could not stimulate blood vessel formation 
in our wound models cause of the absence of active blood network system. Thus 
suggesting that VEGF is not an effective growth factor for inducing angiogenesis and 
wound closure in the organotypic skin biopsies we developed in our lab. For our model, it 
appears that growth factors like EGF, FGF would work efficiently by stimulating 
keratinocyte and fibroblast proliferation and migration.  
The wound models can be personalized according to people with different 
diseased conditions. Partial thickness or full thickness wound culture models can be made 
from each patient and studied accordingly. Wound models can be designed in such a way 
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to have deficiency of specific nutrients or vitamins or minerals as seen in people with 
similar ailments. Though treatment with autologous versus allogenic ASCs does not have 
an immune effect on these wound models, in humans it can cause immunogenic or 
inflammatory response or even rejection by the host. Thus, in patients ASCs need to be 
tested for compatibility before being transplanted. It is conceivable that biopsies are 
obtained at the same time as fat for ASC isolation and by the time the ASCs are at 
passage 3-4 the correct cocktail of growth factors and other molecules could have been 
identified for seeding along with the ASCs. 
ASCs thus act as a suitable candidate for cell therapy owing to its regenerative, 
and paracrine signaling properties. ASCs promote wound healing both in vivo and in 
vitro, though when supplemented with VEGF, accelerates wound closure.  Although 
complete closure was not obtained in the wound cultures treated with ASCs secreting 
VEGF, it is expected that ASCs supplemented with additional growth factors at 
appropriate dosages hold a promising delivery for complete healing of chronic wounds. 
Additionally, it is likely that red light exposure can accelerate healing when combined 
with cell and gene therapy. Thus this study can be personalized to develop an efficient, 
accelerated, less invasive or painful treatment solution for millions of people suffering 
from chronic wounds.
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8. Abbreviations 
 
Acronym Definition 
VEGF Vascular endothelial growth factor 
VPF Vascular permeability factor 
PDGF Platelet derived growth factor 
FGF Fibroblast growth factor 
HGF Hepatocyte growth factor 
KGF Keratinocyte growth factor  
TGF Transforming growth factor 
EGF Epithelial growth factor 
IGF Insulin growth factor 
HBEGF Heparin binding EGF like growth factor 
MIF Macrophage migration inhibitory factor 
TNF  Tumor Necrosis factor 
CSF Colony stimulating factor 
ANGPT Angiopoietin 
ASC Adipose derived stem cells 
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GFP Green fluorescent protein 
AAV Adeno associated virus 
PLGF Placental growth factor 
MAPK Mitogen activated protein kinase 
ECM Extracellular matrix 
PKB Protein kinase B 
MMP Matrix metalloproteinases 
ERK Extracellular regulated kinase 
PI3-K Phosphatidyl inositol 3' kinase 
FAK Focal adhesion kinase 
Flt-1 Fms-related tyrosine kinase 1 
SVF Stromal vascular fraction 
KDR Kinase insert domain 
HIF Hypoxia inducible factor 
PBAE poly β-amino ester 
LLLT Low level light therapy 
ORF Open reading frames 
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ELISA Enzyme-linked immunosorbent assay  
ABAM Antibiotics and antimycotics 
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